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ABSTRACT 
 
In the female reproductive system, the ovary is the primary functional organ responsible 
for oocyte production, follicle maturation and synthesis of sex steroid hormones including 
estrogens. Throughout the lifetime of a female, normal levels of estrogen are critical for the 
proper development and functioning of the ovaries. An alteration in the levels of estrogen can 
result in impaired development of the ovaries, which then adversely affects their response to 
endogenous hormones or exogenous chemicals. Currently, humans are exposed to numerous 
chemicals including organochlorine pesticides that are introduced into the environment on a 
daily basis.  Some of these chemicals exert their toxicity by binding to estrogen receptors in 
inappropriate manners or by inhibiting the ability of endogenous estrogen to bind to its receptors. 
Methoxychlor (MXC; 1,1,1-Trichloro-2,2-bis(4-methoxyphenyl)ethane) is an estrogenic 
organochlorine pesticide that has been shown to cause adverse reproductive outcomes in 
mammalian males and females. Cytochrome P450 enzymes metabolize MXC to mono-hydroxy 
MXC (MOH; 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane) and bis-hydroxy 
MXC (HPTE; 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane). MXC as well as its metabolites 
can interact with ESRs and are known to cause ovarian toxicity. The goal of my doctoral 
dissertation is to determine whether endocrine disruption in the normal estrogenic pathway leads 
to altered sensitivity of the ovaries to environmental chemicals. Specifically, I have used a 
transgenic mouse model in which estrogen receptor alpha (ESR1) is overexpressed (OE) in 
several reproductive and non-reproductive tissues. I hypothesized that the ovaries of ESR1 OE 
mice will be more sensitive to growth inhibition and atresia induced by MXC and its metabolites. 
in vitro as well as in vivo. Results indicate that ovarian antral follicles of ESR1 OE are more 
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sensitive to growth inhibition and atresia induced by MXC and its metabolites compared to 
controls. Moreover, MXC and its metabolites cause differential gene expression of nuclear 
receptors and pro-apoptotic markers in ESR1 OE mouse ovaries compared to control ovaries. 
Furthermore, ESR1 OE mice have lower levels of Cyp3a4 (an enzyme involved in the 
metabolizing pathway of MXC) compared to controls, suggesting that MXC may not be clearing 
out of ESR1 OE animals compared to controls. Collectively, these results suggest that altered 
gene expression of Cyp3a4, nuclear receptors that bind to MXC and pro-apoptotic markers may 
play a vital role in causing ESR1 OE mouse antral follicles to be more sensitive to growth 
inhibition and atresia caused by MXC and its metabolites compare to controls. 
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CHAPTER I 
 
Introduction 
 
 
1.1 Introduction 
 
As a result of an escalating world population, agricultural technology has vastly advanced 
in the past several decades to meet the ever-growing demands for food. Some of the techniques 
employed by farmers include the use of pesticides to preserve crops from being ravaged by 
insects and pests. Insects and pests however, continue to genetically adapt themselves to the 
chemicals, thereby evolving into pesticide-resistant organisms. Consequently, the pesticide 
industry is faced with an ever-growing challenge to formulate and manufacture stringent 
chemicals and toxicants that are released into the environment on a daily basis. Among 
pesticides, organochlorine compounds were a major class of commonly used pesticides. Today, 
numerous organochlorine pesticides have been identified as endocrine disrupting chemicals 
(EDCs), and shown to cause adverse reproductive health outcomes in humans and wildlife 
(Charlier et al., 2002; Hamlin and Guillette, 2010).  EDCs bind to the receptors of hormones 
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secreted by endocrine glands, thereby, interfering with the synthesis, secretion, transport, 
binding, action, or elimination of natural hormones by the body. These chemicals are usually 
either natural products or synthetic chemicals that mimic, enhance (an agonist), or inhibit (an 
antagonist) the action of hormones produced by endocrine organs including the ovaries.  
Several organochlorine pesticides are known to mimic endogenous hormones such as 
estrogens and androgens by binding to receptors and leading to a vast array of reproductive 
disorders (Tiemann, 2008; Windham et al., 2002; Wolff, 1995). An infamous example of an 
estrogenic organochlorine pesticide is dichlorodiphenyltrichloroethane (DDT), which was used 
worldwide for combatting the insect vectors for typhus and malaria worldwide. However, DDT 
is now banned in the US because of its high lipophilic and estrogenic properties, which caused 
bioaccumulation in adipose tissues and resulted in detrimental effects in the reproductive organs 
(ATSDR). Following the ban of DDT in the US in 1972, MXC was widely used as a substitute 
because of its structural similarity to DDT and its shorter half-life. Although MXC does not 
bioaccumulate in adipose tissues to the same extent as DDT, it is known to cause adverse effects 
in the reproductive organs of humans and wildlife because of its estrogenic and androgenic 
properties. Hence, MXC has been extensively studied as a reproductive toxicant, using rodents as 
the animal model. Specifically, MXC has been well characterized as a toxicant that targets 
ovaries in mammalian females (Chapin et al., 1997; Gray et al., 1989; Eroschenko et al., 1995).  
The ovaries of a mammalian female are critical endocrine organs for reproduction 
because they play the dual role of nurturing oocytes as well as synthesizing and secreting sex 
steroid hormones (Hirshfield, 1991). Estrogens, which are sex steroid hormones produced mainly 
by the ovary, are critical for normal fertility, cardiovascular function, maintenance of bones and 
nervous system functions (Britt et al., 2004; Couse and Korach, 1998). The physiological 
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responses of various tissues to estrogens are mediated through ESRs. These receptors are 
localized in the ovary as well as other tissues (Deroo and Korach, 2006). Throughout the lifetime 
of a female, normal levels of estrogens are critical for the proper functioning of the ovaries, 
including the growth and atresia of the functional units of the ovaries called follicles which 
contain oocytes. Atresia is a normal process of cell death that occurs in follicles, and almost 99% 
of follicles present at birth die in this way during the reproductive lifetime of mammalian 
females (Hirshfield, 1991; Richards, 1980). 
While binding of normal levels of endogenous estrogens to ESRs is critical for normal 
growth and atresia (programmed cell death) of follicles, EDCs such as MXC that mimic 
estrogens can disturb the normal pathway of follicular growth or atresia, thereby altering 
reproductive function (Borgeest et al., 2002). The degree and type of damage that takes place 
following toxic insult to the ovary depends on the type of follicle that is targeted by the chemical 
and length of exposure (Hirshfield, 1997). There are several studies that have established that 
MXC is an ovarian toxicant that specifically targets antral follicles (Borgeest et al., 2002; 
Martinez and Swartz, 1991).  Among several adverse effects, which have been detailed in this 
dissertation, inhibition of antral follicle growth and increased atresia of antral follicles are of 
concern as this may result in infertility as well as early menopause or early reproductive 
senescence.  Early menopause in women is a concern because it has been associated with an 
increased risk of chronic diseases such as osteoporosis and cardiovascular disease (Cramer, 
1990; Bagur and Mautalen, 1992).  
The toxicity induced by MXC in the ovaries may not entirely be the effect of the parent 
compound. MXC are metabolized predominantly to 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-
methoxyphenyl)ethane (MOH) and  the bisphenolic compound 1,1,1-trichloro-2,2-bis(4-
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hydroxyphenyl)ethane (HPTE) by cytochrome P450 (CYP450) enzymes (Stresser and Kupfer, 
1997; Stresser and Kupfer, 1998; Kapoor et al., 1970). These enzymes are mainly found in the 
liver, but there is evidence of their presence in the ovaries as well (Symonds et al., 2006). The 
metabolites of MXC induce ovarian toxicity and are endocrine disruptors to a larger extent than 
the parent compound (Miller et al., 2006). Moreover, MOH may be slightly more toxic than 
HPTE in vitro, since MOH causes follicle growth inhibition at an earlier time point and affects 
small antral follicles compared to HPTE (Miller et al., 2006). As mentioned earlier, the adverse 
events occurring in the ovary following exposure to MXC is largely due to its affinity for ESRs. 
However, receptor-binding assays have shown that the metabolites of MXC, MOH and HPTE, 
are more estrogenic than the parent compound. Conversion of MXC to its metabolites is hence 
considered to be a pathway for metabolic activation into a more potent estrogen (Gaido et al., 
1999).  
The goal of this dissertation is to broaden our understanding of the mechanistic pathways 
employed by MXC and its metabolites in inducing toxicity in the ovary, specifically focusing on 
estrogenic pathways. Currently, humans are exposed to numerous chemicals, which are known to 
damage the ovary. Thus, the goal of my doctoral thesis is to determine whether endocrine 
disruption in the normal estrogenic pathway leads to altered sensitivity of the ovaries to MXC 
and its metabolites. Specifically, in my dissertation, I have used a transgenic mouse model in 
which ESR1 is overexpressed (ESR1 OE) in several reproductive and non-reproductive tissues to 
determine if endocrine disruption via ESR1 overexpression alters ovarian response to MXC and 
its metabolites. In Chapter 2, I have described the background and significance of my research as 
well as the generation and validation of ESR1 OE used in my dissertation. In Chapters 3 and 4, I 
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have described experiments that were used to test whether ESR1 overexpression increases the 
sensitivity of the ovaries to MXC and its metabolites.  
The final goal of my dissertation is to analyze whether the ovarian toxicity induced by 
MXC is dependent on dose and exposure period and to analyze the fertility of female mice 
following MXC treatment. However, since the sub-fertility of ESR1 OE mice could be a 
confounding factor, the transgenic ESR1 OE mouse model could not be used to analyze the 
effect of MXC on fertility. Hence, in Chapter 6, I have described experiments in which adult 
female CD-1 mice were treated with varying doses of MXC for several exposure periods. After 
exposure to MXC, some of the treated mice were bred with untreated males to determine the 
fertility of the mice. 
Specific Aim 1: To compare growth of ovarian antral follicles in control and ESR1 OE mice 
treated with MXC and its metabolites. 
I carried out in vitro experiments by treating antral follicles with vehicle, MXC or its 
metabolites. The growth of the antral follicle was monitored for a period of four days. At the end 
of the culture, the follicles were subjected to gene analysis to analyze the gene expression levels 
of nuclear receptors and metabolizing enzymes of MXC. 
Specific Aim 2: To evaluate atresia in control and ESR1 OE mouse antral follicles treated 
with MXC and its metabolites. 
To test this hypothesis, I carried out an in vivo experiment in which I dosed ESR1 OE and 
control mice with vehicle or MXC (8-64 mg/kg/day). One ovary of the mouse was fixed after the 
dosing period to analyze the percentage of atretic antral follicles, while the other ovary was 
processed for protein analyses of pro-apoptotic factors. Additionally, I carried out in vitro 
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experiments by treating antral follicles with vehicle, MXC or its metabolites. Some antral 
follicles were fixed for histological evaluation at the end of the culture and rated according to the 
level of atresia, while others were subjected to analyses of pro-/anti-apoptotic factors.  
Specific Aim 3: To compare the levels of follicular atresia and fertility in CD-1 mice that were 
treated with varying doses of MXC over several dosing periods. 
 These experiments were carried out to analyze the dose and exposure period required by 
MXC to cause increased follicular atresia in CD-1 mouse ovaries compared to controls. CD-1 
female mice were treated with vehicle or varying doses of MXC for 5, 10, 20 and 30 days. 
Further, the mice that were dosed for 30 days were bred with untreated males to analyze fertility 
of the animals after this exposure period.  
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CHAPTER II 
 
Background and Significance 
 
 
2.1 Background and Significance 
 
Ovarian physiology 
The ovary is composed of follicles, which are the primary structural and functional units, 
containing the female germ cells (oocytes) and the somatic cells that surround oocytes. 
(Hirshfield, 1991; Richards, 1980; McGee and Hsueh, 2000). The primordial follicles are the 
earliest form of the follicle containing an oocyte surrounded by a single layer of fusiform 
granulosa cells (Fig. 2.1).  The primordial follicles grow into primary follicles containing a 
slightly larger oocyte surrounded by a single layer of cuboidal granulosa cells. Following this 
stage is the preantral follicle, which is characterized by an oocyte surrounded by 2-4 layers of 
granulosa cells and the beginnings of a thecal cell layer.  Preantral follicles then grow into antral 
follicles, which contain an oocyte surrounded by more than four layers of granulosa cells, an 
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antral space, and two distinct layers of thecal cells (Fig. 2.1) (Barnett et al., 2006; McGee and 
Hsueh, 2000).  
Atresia is a normal process in the ovary that occurs at all stages of follicular development 
throughout the female reproductive lifespan (Gosden and Spears, 1997). When a primordial 
follicle is activated, it is destined to enter the growing follicle pool or to undergo atresia. 
Likewise, during follicular growth and development, approximately 99% of follicles undergo 
atresia due to apoptosis of granulosa cells. Atresia remains a prominent feature of ovarian 
function until all the follicles are exhausted, resulting in reproductive senescence. It is unknown 
why 99% of follicles endowed to the female undergo atresia, while the rest are recruited to 
ovulate (Richards, 1980; Hirshfield, 1991; Tilly, 1996).  
The ovary plays two critical physiological roles in the maintenance of fertility. First, the 
ovary is responsible for follicle development and follicle differentiation (Richards, 1980; 
Hirshfield, 1991). Female mammals are born with a finite number of primordial follicles that can 
mature into antral follicles.  Antral follicles are the only follicle type capable of releasing an egg 
for fertilization (Findlay et al., 2001). Thus, any defect in this pathway would directly reflect on 
the female’s ability to produce viable oocytes needed for fertility. Second, the ovary is 
responsible for synthesizing and secreting sex steroid hormones such as estrogens (Hirshfield, 
1991; McGee and Hsueh, 2000). The estrogens produced by antral follicles bind to ESRs and are 
critical in maintenance of the female reproductive tract as well as non-reproductive tissues such 
as bones, vascular tissues, and the brain (Britt et al., 2004; Deroo and Korach, 2006). 
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Estrogen receptors in the ovary 
Since the discovery of the interactions of estrogens with ESRs in the late 1950s, much 
progress has been made in understanding the mechanisms and manifestation of ESR action. The 
ESR was initially thought to be just a “transporter” to move estrogens from the cytoplasm to the 
nucleus of the cell (Korach et al., 2004; Drummond and Findlay, 1999). However, once the 
structural and functional domains of the ESR were elucidated, the ESR was categorized as a 
ligand-dependent nuclear transcription factor. In the nucleus, ESR exerts its action as a 
transcription factor by recruiting a pre-initiation complex and then binding to estrogen response 
elements (ERE) in promoters of the target gene to initiate gene expression. For more than three 
decades, it was assumed that activating a single receptor brought about the functional effects of 
the ESR. This, however, was proven wrong when a second isomer of ESR was identified and 
cloned about a decade ago – the two isomers were then termed ESR alpha (ESR1) and ESR beta 
(ESR2) (Korach et al., 2004; Fitzpatrick et al., 1999; Woodruff and Mayo, 2005; Drummond et 
al., 2002). 
The ESRs are composed of various domains that are responsible for specific functions 
such as ligand-binding, dimerization, DNA binding and trans-activation (Korach et al., 2004). 
The amino terminal of this receptor consists of a transcription activation domain called the 
activation function-1 (AF-1), followed by the DNA binding domain, whereas the carboxy 
terminal consists of AF-2 as well as the ligand-binding domain.  
In mammals, ESRs are present at multiple sites, thus functioning as critical players in 
normal physiological functions (Deroo and Korach, 2006). In mammalian females, estrogens 
bind to ESRs to facilitate normal development and functioning of the nervous, cardiovascular, 
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skeletal and reproductive systems. Normal levels of estrogens and normal levels of ESRs 
critically govern the development and functioning of the reproductive organs of the mammalian 
female including the ovaries (Britt and Findlay, 2002). In the ovaries, ESR2 is predominantly 
present in the granulosa cells, while ESR1 is predominantly localized in the theca cells of the 
antral follicle (Sar and Welsch, 1999; Fitzpatrick et al., 1999). Due to the specific locations of 
the ESR sub-types, ESR2 is always higher than ESR1 since there are more granulosa cells than 
theca cells in the ovary. Studies have shown that the response of tissues to estrogen is 
specifically dependent on the ratio of ESR1:ESR2 (Hall and McDonnell, 1999; Chang et al., 
2008). Hence, it is critical that estrogens bind to normal numbers of ESR1 and ESR2 binding 
sites in the ovary, to elicit a series of downstream signaling pathways and gene transcription. 
This process is critical for the growth and proliferation of the granulosa and theca cells needed 
for maintaining the health of the oocyte. Thus, any defect in estrogenic signaling, specifically in 
the normal ratio of ESR1 and ESR2 expressed in the ovary, may directly reflect on the female’s 
ability to produce viable oocytes needed for fertility.  
It has been well established that ESR1 and ESR2 act as nuclear transcription factors via 
genomic pathways (Drummond and Findlay, 1999; Korach et al., 2004). In the absence of a 
ligand, the ESR remains in an inactive state by binding to co-repressors such as heat shock 
proteins and immunophilins. The classical genomic pathway is initiated when a ligand (agonist 
or antagonist) binds to the receptor in the cytoplasm of the cell. This causes a conformational 
change in the ESR, leading to the dissociation of co-repressors and allowing the receptor to move 
into the nucleus. In the nucleus, it dimerizes with another ligand-bound ESR via the DNA 
binding domain. The ESR dimer then binds to specific sequences located within the promoter 
region of the target gene termed estrogen response elements (ERE). Once bound, the receptor 
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interacts with coactivators via AF-1 and AF-2 domains to bring about gene transcription (Korach 
et al., 2004; Mueller and Korach, 2001; Bjornstrom and Sjoberg, 2005).  
While estrogen binding to ESR1 and ESR2 is important for normal physiological 
function, several studies show that abnormal levels of estrogen binding to its receptors at 
inappropriate times can lead to problems with ovarian development and function (Colborn et al., 
1993; Jefferson et al., 2007; Roy et al., 2009; Hunt et al., 2009; McLachlan et al., 1982; Nikaido 
et al., 2004). Exposure to endogenous estrogens as well as exogenous estrogenic chemicals 
(compounds that resemble the structure of endogenous estrogens) can alter the expression levels 
of ESR1 and ESR2 by disrupting the gene transcription mechanism in the cells. Such alterations 
in the levels of ESRs can result in impaired development of the ovaries, which in turn adversely 
affects the response of the ovaries to endogenous hormones or exogenous chemicals later in life 
(Sharara et al., 1998; Borgeest et al., 2002a).  
 
ESR1 overexpressing mouse model 
Several studies have illustrated that exposure to estrogenic chemicals can induce ESRs in 
tissues by triggering gene transcription (Jefferson et al., 2002; Patisaul et al., 1999). ESRs may 
also be increased in individuals with genetic polymorphisms (Tanaka et al., 2003). An increase 
either in ESR1 or ESR2 in the ovary may alter the response of the antral follicles to estrogenic 
chemicals such as MXC and its metabolites (Tomic et al., 2006). The antral follicles with 
overexpression of ESRs may be more susceptible to toxicity induced by the chemicals because of 
a higher number of receptor sites available for binding. Moreover, overexpression of either ESR1 
or ESR2 or both may disrupt the normal ratio of ESR1:ESR2 in the ovaries, thus altering the 
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response of antral follicles to exogenous cues. To gain a better insight into the mechanistic 
pathways of chemicals that can increase the sensitivity of the ovaries by altering the estrogenic 
pathway, a transgenic mouse model was generated in which the estrogen receptor component is 
disrupted in the ovaries (Tomic et al., 2007). Specifically, in this mouse model, ESR1 is 
overexpressed in several tissues including the ovaries by transgenic techniques (Fig. 2.2). The 
rationale behind developing such a model is that the ovaries of the mouse model overexpressing 
ESR1 would be sensitive to chemicals that can bind to ESR1.  This would enable the model to be 
used for screening ovarian toxicants such as MXC and its metabolites with ESR1 binding 
properties.  
The transgenic mice for this study were generated using a tetracycline operator promoter 
(Fig. 2.2). A transgene composed of a coding sequence for murine ESR1 was placed under the 
regulatory control of a tetracycline-operator promoter (tet-op). Transcriptional activation of the 
ESR1 transgene is only achieved in the presence of a tetracycline responsive transactivator (tTA) 
protein. tTA protein is produced through an autoregulatory positive feedback mechanism. The 
mice with the tet-op promoter (tet-op-ESR1 mice) were mated to tet-op-tTA/tet-op-luciferase 
mice to produce triple transgenic (tet-op-ESR1/tet-op-tTA/tet-op-luciferase) mice that 
overexpress the estrogen receptor alpha (ESR1 OE). Control mice used in the study were double 
transgenics (tet-op-tTA/tet-op-luciferase), lacking the ESR1 transgene (Tomic et al., 2007).  
 
Validation of ESR1 OE and control mice 
 The mouse model was validated by gene and protein analysis to determine the 
overexpression of ESR1 in the ovaries (Paulose et al., 2011). For analyzing the levels of Esr1 
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mRNA, ovaries of ESR1 OE and control mice were subjected to quantitative real-time PCR 
using Esr1 specific primers. The results indicate that mRNA levels of Esr1 were significantly 
higher in ESR1 OE mice compared to control mice (Fig. 2.3).  
 For analysis of ESR1 protein expression, ESR1 OE and control mice were perfused with 
10% neutral buffered formalin and their ovaries were fixed in 4% paraformaldehyde. 
Immunohistochemical staining of the ovaries was carried out using antibodies specific to ESR1 
(Fig. 2.4A). The staining of ESR1 was seen as deep red stains against a blue counterstain. The 
staining of ESR1 was localized in the theca cells of controls and ESR1 OE ovaries as expected. 
However, in ESR1 OE ovaries (Fig. 2.4 right panel), significantly higher numbers of theca cells 
were stained with ESR1 compared to controls (Fig. 2.4 left panel). This staining was quantified 
by densitometric analysis by pseudocoloring the images using Adobe Photoshop and Image J. 
The results confirmed that ESR1 (densitometric units) was higher in ESR1 OE compared to 
controls. Collectively, these data validate the ESR1 OE mouse model that was used to test the 
hypotheses in this dissertation.  
The general goal of developing this mouse model is to analyze whether the ovaries of 
ESR1 OE mice are more susceptible to estrogenic chemicals and if so, the underlying 
mechanisms required for increased susceptibility. As mentioned earlier, human beings are 
exposed to a host of environmental toxicants that mimic estrogenic behavior. The estrogenic 
chemicals of interest in my research are primarily MXC and secondarily the metabolites of 
MXC, MOH and HPTE.  
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Ovarian toxicity induced by methoxychlor and its metabolites 
There are several reasons why MXC (Fig. 2.5) is the chemical of interest in this 
dissertation. First, MXC has a long environmental half-life ranging from 2-12 months. MXC can 
bind strongly to soil particles and can be carried across rivers and streams; thereby exposing 
MXC to regions where its usage is minimal (Golovleva et al., 1984).   
Second, MXC is an environmental estrogen and exposure to MXC has been shown to 
cause adverse effects in the female reproductive system. In one study, exposure of female rats to 
25-100 mg/kg-day of methoxychlor beginning on post-natal day 21 caused premature vaginal 
opening and early first estrus. In the same study, it was noted that estrous cyclicity started earlier 
in animals exposed to 25 mg/kg-day, at a normal age in animals exposed to 50-100 mg/kg-day, 
and was delayed in animals dosed with 200 mg/kg-day (Gray et al., 1989). Other adverse effects 
reported with MXC exposure in mammalian females include persistent estrus, vaginal 
cornification, increased cell proliferation, increased reproductive tract weights, reduced ovulation 
and decreased steriodogenesis. These effects are notable because they are characteristic of a 
chemical that mimics estrogenic behavior (Eroschenko et al., 1995; Eroschenko and Cooke, 
1990; Gray et al., 1989).  
Third, studies have shown that MXC targets antral follicles specifically (Borgeest et al., 
2002b; Martinez and Swartz, 1991). Studies in our laboratory have shown that MXC inhibits 
antral follicle growth in vitro and increases atresia of antral follicles after in vivo and in vitro 
exposure (Gupta et al., 2006; Miller et al., 2005). Although atresia is a common process in 
healthy ovaries, an increase in atresia would be detrimental because it would result in a faster 
depletion of antral follicles (Hirshfield, 1991). This is of concern because, in the lifetime of 
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mammalian females, only a finite number of antral follicles are recruited to ovulate, and hence, 
depletion of this finite pool could result in early reproductive senescence and other adverse 
health outcomes (Byskov et al., 2005; Bagur and Mautalen, 1992). One possible mechanism by 
which MXC increases atresia is by inducing oxidative stress in the ovary (Gupta et al., 2006). 
Oxidative stress has been associated with the release of cytochrome c from the mitochondria, 
which is a key first step in the apoptotic pathway (Tilly and Tilly, 1995). Cytchrome c binds to 
apoptosis protease activating factor-1 (apaf-1) and caspase-9 and together these factors initiate 
the cleavage of caspase-3. Caspases (cysteine aspartate-specific proteases) are the main effector 
molecules that are activated and caspase-3 is the final executioner of apoptosis in the cell 
(Johnson and Bridgham, 2002; Boone and Tsang, 1998; Fenwick and Hurst, 2002). B-cell 
lymphoma/leukemia protein-2 (Bcl-2) is an anti-apoptotic factor and prevents the release of 
cytochrome c from the mitochondria and this blocks the subsequent caspase cascade. Bcl2 
associated X protein (Bax) is a pro-apoptotic factor and can induce the release of cytochrome c 
from the mitochondria. Previous studies have shown that MXC increases Bax levels while not 
affecting Bcl-2 levels after in vivo exposure (Borgeest C et al., 2004). Moreover, Bax-deletion 
and Bcl-2 overexpression provide some protection from MXC induced toxicity (Miller et al., 
2005). Furthermore, when antral follicles were co-treated with estradiol and MXC, the antral 
follicles were protected from undergoing atresia. Estradiol is an anti-oxidant and has also been 
shown to up-regulate Bcl-2 levels through non-genomic pathways, both of which could be 
possible reasons for the observed protection (Miller et al., 2006). 
Finally, the metabolites of MXC are more potent estrogens than the parent compound. 
MXC is metabolized in the liver as well as in the ovary by CYP450 enzymes to MOH and HPTE 
(Fig. 2.6) (Stresser and Kupfer, 1997; Stresser and Kupfer, 1998; Kapoor et al., 1970). CYP1A2 
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and CYP2C29 are the key enzymes that break down MXC to MOH in mice, whereas CYP3A4 
breaks down the metabolites to more soluble compounds to facilitate excretion (Stresser and 
Kupfer, 1997; Stresser and Kupfer, 1998). In vitro studies have shown that, like MXC, the 
metabolites inhibit antral follicle growth and increase atresia in antral follicles (Miller et al., 
2006). However, they are more potent than MXC because these adverse effects are seen with 10-
fold lower concentrations than MXC. Further, it has been shown that MOH is more toxic than 
HPTE even though HPTE has a higher affinity for ESR1 compared to MOH (Miller et al., 2006; 
Gaido et al., 1999).  
The goals of this dissertation are first, to broaden our understanding of the mechanistic 
pathways employed by MXC and its metabolites in inducing toxicity in the ovary and second, to 
understand differential responses elicited in the ESR1 OE ovary when exposed to MXC and its 
metabolites. Besides this, there is limited knowledge about how ovaries respond normally to 
estrogenic chemicals versus how they respond when normal estrogenic pathways are disrupted. 
Normal estrogenic pathways may be disrupted after exposure to chemicals, by genetic 
polymorphisms or in cancerous tissues. Disruption may occur as a result of decreasing or 
increasing levels of ESRs in the tissue. As a first step, in my dissertation, I have examined how 
overexpression of ESR1 leads to increased susceptibility of the ovaries to estrogenic chemicals. 
There are numerous environmental estrogens that women are exposed to on a daily basis. Hence, 
by using MXC as a model estrogenic chemical and ESR1 OE mice as a tool, estrogenic 
chemicals with similar characteristics can be screened. 
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2.2 Figures and Legends 
Figure 2.1 
 
 
 
 
 
 
Follicular development in the ovary – the ovary is composed of structural and functional units called 
follicles. The earliest form of the follicles is the primordial follicle followed by the primary and pre-antral 
follicle and finally, the antral follicle. 
 
 
 
 
 
 
 
 
 22 
Figure 2.2 
 
 
 
 
 
 
 
 
 
 
Schematic of the transgenes used to generate the mice used in this study. ESR1 overexpressing (ESR1 
OE) triple transgenic (tet-op-tTA/tet-op-luciferase/tet-op-ESR1) and double transgenic (tet-op-tTA/tet-op-
luciferase) control mice were used in the study. 
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Figure 2.3 
 
 
 
 
 
 
 
 
 
Esr1 mRNA levels in ovaries of ESR1 OE mice. Ovaries were isolated from adult cycling ESR1 OE and 
control mice and gene expression of Esr1 was measured by q-PCR techniques and normalized to the 
reference gene β-actin. Each bar represents means ± SE from three separate experiments. Asterisk (*) 
indicates statistically significant differences from controls (n=3, p≤0.05).  
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Figure 2.4 
A 
 
 
 
 
 
B 
 
 
 
 
 
ESR1 protein expression in ESR1 OE and control mouse ovaries. Ovaries were isolated from adult 
cycling ESR1 OE and control mice and subjected to protein analysis. (A) Protein expression of ESR1 was 
analyzed by immunohistochemical staining of ESR1 in ovarian sections (20X magnification) of control 
(right panel) and ESR1 OE (left panel) mice. Red = ESR1 staining; Blue = counterstain. GC = granulosa 
cells; TC = theca cells; Ov = oviduct. (B) Immunohistochemical staining was quantified and presented as 
a bar graph. Each bar represents means ± SE from three separate experiments. Asterisk (*) indicates 
statistically significant differences from controls (n=3, p≤0.05).  
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Figure 2.5 
 
 
 
 
 
 
 
 
Chemical structure of the organochlorine pesticide methoxychlor [1,1,1-trichloro-2,2-bis(4-
methoxyphenyl)ethane]. 
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Figure 2.6 
 
 
MXC is metabolized predominantly to 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane 
(MOH) and  the bisphenolic compound 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane (HPTE) by 
cytochrome P450 (CYP450) enzymes present in the liver and ovaries. 
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CHAPTER III 
 
Increased sensitivity of estrogen receptor alpha overexpressing mouse antral follicles to 
growth inhibition induced by methoxychlor and its metabolites 
 
3.1 Abstract 
Methoxychlor (MXC), an organochlorine pesticide, and its metabolites, mono-hydroxy 
MXC (MOH) and bis-hydroxy MXC (HPTE) are known ovarian toxicants and can cause 
inhibition of antral follicle growth. Since these chemicals bind to estrogen receptor alpha 
(ESR1), we hypothesized that ovaries overexpressing ESR1 (ESR1 OE), would be more 
susceptible to toxicity induced by MXC and its metabolites. We cultured antral follicles from 
controls and ESR1 OE mouse ovaries with either the vehicle dimethylsulfoxide (DMSO), MXC, 
MOH or HPTE. The data show that at 96h, the cultured antral follicles from ESR1 OE antral 
follicles are more susceptible to toxicity induced by MXC, MOH and HPTE because low doses 
of these chemicals cause follicle growth inhibition in ESR1 OE mice but not in control mice. On 
comparing gene expression levels of nuclear receptors in the cultured antral follicles of ESR1 OE 
and control follicles, we found differential mRNA expression of Esr1, estrogen receptor beta 
(Esr2), androgen receptor (Ar), progesterone receptor (Pr) and aryl hydrocarbon receptor (Ahr) 
between the genotypes. We also analyzed mRNA levels of Cyp3a41a, the enzyme metabolizing 
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MOH and HPTE, in the cultured follicles and found that Cyp3a41a was significantly lower in 
DMSO-treated ESR1 OE follicles compared to controls. In ESR1 OE livers, we found Cyp3a41a 
levels were significantly lower compared to control livers. Collectively, these data suggest that 
MXC and its metabolites cause differential gene expression in ESR1 OE mice compared to 
controls. The results also suggest that the increased sensitivity of ESR1 OE mouse ovaries to 
toxicity induced by MXC and its metabolites is due to low clearance of the metabolites by the 
liver and ovary. 
 
3.2 Introduction 
 MXC is a broad-spectrum organochlorine pesticide and is a model compound for 
environmental estrogens because it has been shown to have pro- and anti-estrogenic activity 
(Cummings, 1997).  Although MXC has a short half-life in mammals, it can persist in the 
environment for a considerable amount of time because it binds strongly to soil particles 
(Golovleva et al., 1984). Hence, decades of MXC usage can result in considerable amounts of 
the pesticide persisting in the environment even in areas where direct exposure is minimal. The 
estrogenic activity of MXC has drawn attention because of its undesirable effects on mammalian 
female reproduction (Bulger et al., 1978; Gray et al., 1988). Previous studies have demonstrated 
that MXC treatment causes adverse ovarian effects such as increased atresia (programmed cell 
death) of antral follicles and proliferation of ovarian surface epithelium in mice (Borgeest et al., 
2002). 
Mammalian female reproduction is entirely dependent on the proper development and 
functioning of antral follicles (Hirshfield, 1991). Being the only follicle type that can release the 
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oocyte for fertilization, the antral follicle plays a crucial role in reproduction. Besides this, the 
antral follicle can synthesize and secrete sex steroid hormones such as estrogens, which are 
critical for the growth of the follicles (Hsueh et al., 1984). The estrogens produced by antral 
follicles bind to estrogen receptors alpha and beta (ESR1 and 2) located in the ovary to bring 
about normal menstrual or estrous cyclicity and maintenance of the female reproductive tract 
(Matthews and Gustafsson, 2003). In the ovary, ESR1 is predominantly expressed in the ovarian 
surface epithelium and theca cells while ESR2 is largely localized in the granulosa cells (Couse 
et al., 1997b). While estrogen binding to ESRs is important for normal physiological functions, it 
is critical that the levels of ESRs in the body be normal (Couse et al., 1997a). However, in 
certain cases, genetic polymorphisms may cause abnormalities in gene expression levels 
resulting in an overexpression of estrogen receptors (Tanaka et al., 2003). Overexpression of 
estrogen receptors may also be caused by exposure to estrogenic chemicals that bind to ESRs 
and block endogenous estrogen from binding to the receptors (Danzo, 1997). Binding of 
estrogenic chemicals to ESRs may hinder the normal functioning of the receptor as well as cause 
aberrant gene transcription, leading to an induction of ESR gene expression in the ovary 
(Jefferson et al., 2002; Patisaul et al., 1999). Overexpression of ESRs may make the ovary more 
susceptible to further toxic insult because of an increased number of binding sites for estrogenic 
chemicals.  
In this study, we focused on whether overexpression of ESR1 in the ovary results in an 
increased susceptibility of the antral follicles to toxicity induced by MXC or its metabolites. 
MXC is metabolized predominantly to MOH and HPTE by cytochrome P450 (Cyp) enzymes 
(Stresser and Kupfer, 1997; Stresser and Kupfer, 1998; Kapoor et al., 1970). Cyp1a2 and 
Cyp2c29 convert MXC to MOH and HPTE while Cyp3a41a converts MOH and HPTE to water-
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soluble compounds that can be excreted from the body (Stresser and Kupfer, 1997; Stresser and 
Kupfer, 1998). 
Overexpression of ESR1 in the mouse ovary was achieved by transgenic techniques as 
previously described (Tomic et al., 2007). Previous results have shown that administration of 
MXC in ESR1 OE in vivo caused an increase in the percentage of atretic antral follicles 
compared to control animals (Tomic et al., 2006). MXC and its metabolites are also known to 
cause growth inhibition of antral follicles in vitro (Miller et al., 2005; Miller et al., 2006; Gupta 
RK et al., 2006) and hence, this study was designed to determine whether overexpression of 
ESR1 increases the susceptibility of antral follicles to growth inhibition induced by MXC and its 
metabolites compared to controls. Moreover, MXC and its metabolites have also been shown to 
cause downstream gene transcription/alterations in several species and cell types (Gaido et al., 
1999; Gaido et al., 2000; Waters et al., 2001). However, little information is available on the 
effects of MXC, MOH and HPTE separately on gene expression levels of receptors such as Esr1, 
Esr2, Ar, Pr and Ahr and the metabolizing enzymes Cyp1a2, Cyp2c29 and Cyp3a41a in mouse 
antral follicles. Hence, we analyzed whether the estrogenic compounds MXC or its metabolites 
are able to cause changes in gene transcription in ESR1 OE and control antral follicles after in 
vitro treatment. We hypothesized that MXC and its metabolites may cause differential gene 
expression in ESR1 OE antral follicles compared to controls because of the increased number of 
ESR1 receptors in ESR1 OE that can bind MXC and its metabolites in the ovaries. 
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3.3 Materials and Methods 
 
Animals  
ESR1 OE and control mice were used for all experiments. The mice were housed in the 
University of Illinois Veterinary Medicine core animal facility under a 12:12 dark:light cycle and 
provided food and water ad libitum. Only triple transgenic ESR1 OE (tet-op-ESR1/tet-op-
tTA/tet-op-luciferase) and double transgenic control (tet-op-tTA/tet-op-luciferase) mice were 
used for the experiments. All animal procedures were approved by the University of Illinois 
Institutional Animal Care and Use Committee. 
 
Chemicals 
MXC (99% pure) was purchased from Chemservice (West Chester, PA). MOH and 
HPTE (99% pure) were synthesized in Dr. Vincent Njar’s laboratory (University of Maryland, 
Baltimore now at Thomas Jefferson University, Philadelphia, PA). Stock solutions of MXC, 
MOH and HPTE for in vitro dosing were prepared using dimethylsulfoxide (DMSO) (Sigma, St. 
Louis MO) as a solvent.  
 
Follicle culture 
Antral follicles (determined by appearance and relative size) were isolated from ESR1 
OE and control ovaries using fine watchmaker forceps. About 75-80 antral follicles (300-400 
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µm) were obtained from at least two mice of each genotype per experiment. The follicles were 
then randomly divided into five groups – non-treatment (NT), vehicle-control (DMSO) and three 
chemical treatments of MXC, MOH or HPTE. Increasing concentrations (1.33, 13.3 and 133 
mg/ml) of MXC and (0.133, 1.33 and 13.3 mg/ml) of MOH and HPTE were made to allow an 
equal volume to be added to each of the treatment groups in the 96-well culture plate to control 
the solvent concentration. The final concentrations of MXC in each well of the culture were 1, 10 
and 100 µg/ml. Similarly, final concentrations of MOH and HPTE in culture were 0.1, 1, and 10 
µg/ml. MOH and HPTE were used at 10-fold lower concentrations than MXC because the 
metabolites of MXC are thought to be more toxic than the parent compound. Moreover, the 
amount of the metabolites reaching the follicles after MXC has been metabolized is likely to be 
lower than the parent compound. In the vehicle control treatment group, DMSO was used at 
0.075% which is not toxic to cultured follicles. The doses selected for in vitro studies were based 
on previously published studies showing that these concentrations of MXC, MOH and HPTE 
induce toxicity in antral follicles and granulosa cell culture models (Miller et al., 2005; Gupta et 
al., 2006). A non-treatment group was included to control for culture conditions and follicles in 
this group were placed only in supplemented α-MEM devoid of either DMSO or chemicals.  
The follicles were cultured in supplemented α-MEM as described previously. Briefly, 
supplemented α-MEM was prepared using 1% ITS (10 ng/ml insulin, 5.5 ng/ml transferrin, 5.5 
ng/ml selenium), 100 U/ml penicillin, 100 mg/ml streptomycin, 5 IU/ml human recombinant 
follicle-stimulating hormone (FSH; Dr. A. F. Parlow, National Hormone and Peptide Program, 
Harbor-UCLA Medical Center, Torrance, CA), and 5% fetal calf serum (Atlanta Biologicals, 
Lawrenceville, GA). Follicles were incubated for 96 hrs at 37°C in 95% air and 5% CO2.  
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Growth analysis of follicles in culture 
Antral follicles were cultured for 96 hrs and follicle growth was examined at 24 hr 
intervals using published methods (Gupta RK et al., 2006). Briefly, starting on the day of culture 
(0h) follicles in the culture wells were measured every 24h using an inverted microscope 
equipped with a calibrated ocular micrometer. Follicle diameter measurements were measured in 
perpendicular axes, averaged among treatment groups and plotted to compare the effects of 
chemical treatments on growth over time. Data were analyzed as percent change of diameter 
from the 0h time point. 
 
Gene analysis 
Gene expression analysis was carried out on liver samples as well as cultured antral 
follicles. Liver samples were taken from adult female ESR1 OE and control mice. Total RNA 
from liver samples was extracted using RNeasy Mini Kit (Qiagen, Inc., Valencia, CA) as per the 
manufacturer’s protocol. Cultured antral follicles were collected from 96-well plates and snap-
frozen in liquid nitrogen. Total RNA was extracted from follicles using the RNeasy Micro Kit 
(Qiagen, Inc., Valencia, CA) by homogenizing the follicles in buffer according to the 
manufacturer’s protocol. Total RNA (100-500 ng) from liver and follicles were then reverse 
transcribed to obtain complementary DNA (cDNA) using an iScript cDNA synthesis kit (Bio-
Rad Laboratories, Inc., Hercules CA) according to the manufacturer’s protocol. Quantitative 
real-time (q-PCR) was conducted using a CFX96 Real-Time PCR Detection System (Bio-Rad 
Laboratories, Inc., Hercules CA) and accompanying software according to the manufacturer's 
instructions. The machine quantifies the amount of q-PCR product generated by measuring the 
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dye (SsoFast EvaGreen from Bio-Rad Laboratories, Inc., Hercules CA) that fluoresces when 
bound to double-stranded DNA.  A standard curve was generated from five serial dilutions of 
purified q-PCR product. To detect genomic DNA contamination, a well containing total RNA 
was included each time. Gene-specific primers (synthesized by Integrated DNA Technologies, 
Inc.,Coralville, Iowa) were used for the q-PCR (Table 3.13) and mouse β-actin was used as the 
reference gene. An initial incubation of 95°C for 10 min was followed by 40–50 cycles of 94°C 
for 10 s (denaturation step), 55°- 60°C (annealing step) for 10 s, and 72 °C for 10 s (extension 
step), along with a final extension at 72 °C for 10 min. Starting quantity (SQ), an arbitrary term 
generated by CFX96, denotes the relative gene expression level in the experimental samples. 
These values are calculated based on the standard curve and are read at the cycle at which the 
gene begins amplifying exponentially.  For each gene, a melting curve was performed at 55–
90 °C to monitor the generation of a single product. SQs from ESR1 OE and control samples 
were normalized by obtaining the ratio of gene:β-actin. The specificity of the primers was 
verified by the lack of amplification from genomic DNA and by a single melting curve. For liver 
samples, fold changes were calculated as a ratio of normalized values of ESR1 OE samples and 
mean normalized values of controls.  All experiments were performed in triplicate. 
 
Statistical analysis 
All data were analyzed using SPSS statistical software (SPSS, Inc., Chicago, IL). Data 
were expressed as means ± SEM from at least three separate experiments. Multiple comparisons 
between experimental groups were done using analysis of variance (ANOVA) followed by 
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Tukey's post hoc comparison. Comparison between two groups was done using Student’s t-test. 
Statistical significance was assigned at p≤0.05. 
 
3.4 Results 
 
MXC and its metabolites cause increased growth inhibition in antral follicles of ESR1 OE 
compared to controls 
Growth analysis of ESR1 OE and control antral follicles treated with MXC shows that 
after 96h of culture, 10 and 100 µg/ml MXC inhibited growth of follicles compared to DMSO-
treated follicles (Fig. 3.1). However, in ESR1 OE mice, follicles treated with even the lowest 
dose of 1 µg/ml MXC had growth inhibition compared to control follicles.   
 With MOH treatment, 1 and 10 µg/ml MOH inhibited growth of control follicles 
compared to DMSO-treated follicles. However, in ESR1 OE mice, all three doses of MOH (0.1, 
1 and 10 µg/ml) inhibited growth of antral follicles (Fig. 3.2). 
 HPTE treatment also caused differences in antral follicle growth between ESR1 OE and 
control mice (Fig. 3.3). In control animals, the growth of antral follicles was not inhibited with 
any of the three doses of HPTE compared to DMSO-treated follicles (Fig 3.3 A). However, in 
ESR1 OE antral follicles, 10 µg/ml HPTE significantly inhibited follicle growth as early as 48 h 
compared to DMSO treatment (Fig 3.3 B). Significant growth inhibition by 1 µg/ml HPTE was 
seen by 72h compared to DMSO treatment and by 96h even the lowest dose caused a significant 
inhibition of antral follicle growth compared to DMSO treated antral follicles. 
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MXC and its metabolites cause differential gene expression of nuclear receptors in antral 
follicles of ESR1 OE and controls 
 Since ESR1 is a nuclear transcription factor which, upon ligand binding, can cause gene 
transcription of various genes including nuclear receptors (Murdoch and Gorski, 1991), ESR1 
OE and control antral follicles treated with MXC, MOH and HPTE in vitro were subjected to q-
PCR to analyze mRNA levels of nuclear receptors including Esr1, Esr2, Ar, Ahr and Pr. The 
results show that MXC treatment caused differential gene expression of Esr1 in controls and 
ESR1 OE (Fig. 3.4A). In controls, MXC treatment caused a dose dependent decrease in Esr1 
mRNA and was significantly reduced at the highest dose of treatment compared to DMSO 
treated follicles (Fig. 3.4A-left panel; controls: DMSO = 0.2 SQ ± 0.1; 1 µg/ml MXC = 0.1 SQ ± 
0.002; 10 µg/ml MXC = 0.06 SQ ± 0.02; 100 µg/ml MXC = 0.03 SQ ± 0.02; n = 13-15 follicles 
from 5 separate experiments; p ≤ 0.05). In ESR1 OE mice, the mRNA levels of Esr1 increased in 
a dose dependent manner and were significantly higher than controls in follicles treated with 100 
µg/ml MXC compared to DMSO treated follicles (Fig. 3.4A-right panel; ESR1 OE: DMSO = 5.0 
SQ ± 0.9; 1 µg/ml MXC = 4.4 SQ ± 0.4; 10 µg/ml MXC = 10.0 SQ ± 3.1; 100 µg/ml MXC = 
29.0 SQ ± 7.0; n = 13-15 follicles from 5 separate experiments; ; p ≤ 0.05).  
In follicles treated with MOH and HPTE, mRNA levels of Esr1 were significantly higher 
in ESR1 OE antral follicles compared to controls (Figs. 3.4B and 3.4C). However, gene 
expression levels did not differ between the treatment groups in either genotype when compared 
to DMSO treated follicles.  
 MXC (10 µg/ml) significantly up-regulated Esr2 levels in controls and ESR1 OE antral 
follicles. However, Esr2 levels in controls were significantly higher than ESR1 OE antral 
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follicles at this concentration (Fig. 3.5A; controls: DMSO = 0.4 SQ ± 0.2; 10 µg/ml MXC = 1.6 
SQ ± 0.1; ESR1 OE: DMSO = 0.5 SQ ± 0.02; 10 µg/ml MXC = 1.07 SQ ± 0.1; n = 13-15 
follicles from 3 separate experiments; p ≤ 0.05). 
With MOH treatment, Esr2 was up-regulated significantly at 10 µg/ml in ESR1 OE mice 
compared to controls; while in control follicles, levels of Esr2 were not different between 
treatment groups (Fig. 3.5B; controls: DMSO = 0.4 SQ ± 0.02; 10 µg/ml MOH = 1.21 SQ ± 0.5; 
ESR1 OE: DMSO = 0.43 SQ ± 0.06; 10 µg/ml MOH = 1.46 SQ ± 0.06; n = 13-15 follicles from 
3 separate experiments). HPTE treatment of antral follicles significantly up-regulated Esr2 levels 
at 10 µg/ml in both genotypes (Fig. 3.5C; controls: DMSO = 0.3 SQ ± 0.01; 10 µg/ml HPTE = 
1.77 SQ ± 0.02; ESR1 OE: DMSO = 0.37 SQ ± 0.05; 10 µg/ml HPTE = 1.72 SQ ± 0.22; n = 13-
15 follicles from 3 separate experiments; p ≤ 0.05).  
 MXC treatment caused a dose-dependent increase in the levels of Ar in ESR1 OE and 
control antral follicles (Fig. 3.6A). In both genotypes, 100 µg/ml MXC caused a significant 
increase in the levels of Ar compared to DMSO treated follicles. However, the levels of Esr2 
were significantly higher in ESR1 OE antral follicles compared to control antral follicles with 
100 µg/ml MXC treatment (Controls: DMSO = 26.9 SQ ± 4.3; 100 µg/ml MXC = 49.6 SQ ± 7.1; 
ESR1 OE: DMSO = 25.5 SQ ± 2.6; 100 µg/ml MXC = 87.5 SQ ± 8.9; n = 13-15 follicles from 3 
separate experiments; p ≤ 0.05). MOH and HPTE treatment did not have any effect on Ar levels 
in ESR1 OE or control antral follicles (Figs. 3.6B and 3.6C).  
 MXC treatment did not cause any change in Pr levels in ESR1 OE treated antral follicles. 
However in control follicles, Pr levels at 10 and 100 µg/ml MXC were significantly increased 
compared to DMSO treated antral follicles (Fig 3.7A). At these doses of MXC, Pr levels in 
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control follicles were significantly higher than ESR1 OE follicles as well (Controls: DMSO = 0.9 
SQ ± 0.02; 10 µg/ml MXC = 1.9 SQ ± 0.1; 100 µg/ml MXC = 2.1 SQ ± 0.3; ESR1 OE: DMSO = 
1.0 SQ ± 0.1; 1 µg/ml MXC = 1 SQ ± 0.1; 10 µg/ml MXC = 1.2 SQ ± 0.1; 100 µg/ml MXC = 1.4 
SQ ± 0.2; n = 13-15 follicles from 3 separate experiments; p ≤ 0.05). MOH or HPTE treatments 
did not alter Pr levels in either genotype (Figs. 3.7B and 3.7C). 
MXC treatments did not affect levels of Ahr in either genotype (Fig. 3.8A). In MOH and 
HPTE treated antral follicles, 10 µg/ml treatment significantly decreased the levels of Ahr in 
ESR1 OE mice compared to DMSO, 0.1 and 1 µg/ml treatments (Figs. 3.8B and 3.8C). 
However, MOH treatment had no effect on the levels of Ahr in control follicles (Figs 7B; 
controls: DMSO = 6.1 SQ ± 0.5; 10 µg/ml MOH = 4.3 SQ ± 0.8; ESR1 OE: DMSO = 6.6 SQ ± 
0.4; 10 µg/ml MOH = 3.84 SQ ± 0.2; n = 13-15 follicles from 3 separate experiments; Fig. 7C; 
controls: DMSO = 65.8 SQ ± 7; 10 µg/ml HPTE = 44.9 SQ ± 2.1; ESR1 OE: DMSO = 75.6 SQ 
± 6.6; 10 µg/ml HPTE = 53.9 SQ ± 2.4; n = 13-15 follicles from 3 separate experiments; p ≤ 
0.05). 
 
MXC and its metabolites cause differential gene expression of metabolizing enzymes in antral 
follicles of ESR1 OE and controls 
 Since Cyp1a2 and Cyp2c29 are involved in the metabolism of MXC and its metabolites 
(Stresser and Kupfer, 1998), we analyzed the mRNA levels of these enzymes in antral follicles 
cultured with MXC and its metabolites. MXC treatment significantly induced Cyp1a2 in control 
follicles at 10 µg/ml compared to the DMSO, 1 and 100 µg/ml treated follicles. However, in 
ESR1 OE follicles, MXC treatment significantly induced Cyp1a2 at the 100 µg/ml concentration 
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compared to DMSO, 1 and 10 µg/ml treatment groups. Interestingly, at 100 µg/ml MXC, Cyp1a2 
induction was significantly greater in ESR1 OE follicles compared to controls (Fig 3.9A 
controls: DMSO = 15.5 SQ ± 3.0; 100 µg/ml MXC = 16.3 SQ ± 2.3; ESR1 OE: DMSO = 26.2 
SQ ± 5; 100 µg/ml MXC = 57.7 SQ ± 7.8; n = 13-15 follicles from 3 separate experiments; p ≤ 
0.05). MOH or HPTE did not have any effect on Cyp1a2 in any of the treatment groups 
compared to DMSO treatment (Figs. 3.9B and 3.9C). 
 MXC treatment significantly induced Cyp2c29 in control follicles at 10 µg/ml compared 
to DMSO treated follicles, whereas in ESR1 OE follicles, MXC treatment significantly induced 
Cyp2c29 at the 100 µg/ml concentration compared to DMSO treated follicles. Similar to Cyp1a2, 
at 100 µg/ml MXC treatment, Cyp2c29 induction was significantly greater in ESR1 OE follicles 
compared to controls (Fig. 3.10A; controls: DMSO = 01.7 SQ ± 0.1; 100 µg/ml MXC = 3.1 SQ ± 
0.3; ESR1 OE: DMSO = 2.36 SQ ± 0.63; 100 µg/ml MXC = 7.34 SQ ± 1; n = 13-15 follicles 
from 3 separate experiments; p ≤ 0.05). MOH or HPTE did not affect Cyp2c29 in any of the 
treatment groups compared to DMSO treatment (Figs. 3.10B and 3.10C). 
 Since Cyp3a41a is involved in the metabolism of MOH and HPTE (Stresser and Kupfer, 
1997), we analyzed the levels of Cyp3a41a in follicles treated with these chemicals. The results 
indicate that Cyp3a41a was significantly lower in DMSO treated follicles of ESR1 OE compared 
to controls (Figs. 3.11A; controls: DMSO = 56.2 SQ ± 7.8; ESR1 OE: DMSO = 28.9 SQ ± 3.3; 
Fig. 3.11B; controls: DMSO = 23.5 SQ ± 2.1; ESR1 OE: DMSO = 8.9 SQ ± 0.5; n = 13-15 
follicles from 3 separate experiments; p ≤ 0.05).    
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Gene expression of Cyp3a41a is lower in ESR1 OE livers compared to controls 
 Since we found significantly low levels of Cyp3a41a in DMSO treated follicles in vitro, 
we analyzed the fold-change in gene expression levels of Cyp1a2, Cyp2c29 and Cyp3a41a 
between liver tissues of ESR1 OE and control mice. While there was no difference in the fold-
change levels of Cyp1a2 and Cyp2c29 between ESR1 OE and control livers (Figs. 3.12A and 
3.12B), fold-change level of Cyp3a41a was significantly lower in ESR1 OE livers compared to 
controls (Fig. 3.12C; controls = 1 SQ; ESR1 OE = 0.43 SQ ± 0.2; n = 5; p ≤ 0.05). 
 
3.5 Discussion 
 
  Our present study shows that ESR1 OE antral follicles treated with MXC have increased 
growth inhibition compared to controls, indicating that ESR1 OE antral follicles are more 
sensitive to MXC-induced growth-inhibition than controls. This is consistent with previous 
studies in which in vivo MXC treatment resulted in a higher percentage of atretic antral follicles 
in ESR1 OE mice compared to controls (Tomic et al., 2006). When we analyzed growth in 
follicles treated with the metabolites of MXC, we found that the lower dose of MOH caused a 
significant growth inhibition in ESR1 OE follicles compared to control follicles. We also found 
that while HPTE did not inhibit growth in control follicles, it inhibited growth in ESR1 OE antral 
follicles. This concurs with previous findings that MOH is more toxic to antral follicles than 
HPTE (Miller et al., 2006). However, ESR1 OE follicles treated with HPTE have growth 
inhibition by 48h while MOH treated follicles (0.1 and 1 µg/ml) have growth inhibition only by 
96h, which suggests that ESR1 OE follicles are more sensitive to toxicity induced by HPTE than 
MOH. This could be because HPTE has a greater affinity for ESR1 than MXC (Gaido et al., 
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1999) and possibly MOH and hence can bind to the higher numbers of ESR1 in ESR1 OE 
follicles at a faster rate inducing toxicity at an earlier time-point compared to controls.  
 ESR1 belongs to a large superfamily of nuclear hormone receptors that share a common 
structural organization comprising domains that are responsible for specific functions such as 
ligand binding, dimerization, DNA binding, and trans-activation (Murdoch and Gorski, 1991). In 
this study, we determined whether MXC and its metabolites cause differential gene expression of 
nuclear receptors Esr1, Esr2, Ar, Pr and Ahr in ESR1 OE mice compared to controls. Our results 
show that, with MXC treatment, there is a dose-dependent down-regulation of Esr1 in control 
antral follicles, whereas in ESR1 OE follicles there is a dose-dependent induction of Esr1. These 
data suggest that MXC is acting differentially in ESR1 OE and control follicles because of the 
ratio of ESR1 and ESR2 expressed in these tissues. In control antral follicles, ESR2 is higher 
because granulosa cells predominantly express ESR2, while theca cells predominantly express 
ESR1. However in ESR1 OE follicles, ESR1 is higher than ESR2 because of the transgenic 
overexpression of Esr1 in the theca and interstitium of ESR1 OE antral follicles. The relative 
levels of ESR1 and ESR2 are critical for determining the sensitivity and specificity of responses 
of tissues to estrogens and estrogenic chemicals such as MXC and its metabolites (Chang et al., 
2008; Hall and McDonnell, 1999). Studies have indicated that various estrogenic chemicals will 
cause varied phenotypes in tissues that express predominantly ESR1 compared with those 
expressing ESR2 by differential gene transcription (Tee et al., 2004; Waters et al., 2001). 
Moreover, studies done on the structure activity relationships of ESRs with their ligands show 
that the ligand determines the specificity of co-regulators binding to response elements (Tee et 
al., 2004). Hence, it is possible that in tissues overexpressing ESR1, MXC is binding 
predominantly to the overexpressed ESR1 and recruiting co-activators to auto-induce gene 
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transcription of Esr1. However, in control tissues, MXC is interacting predominantly with ESR2 
and down-regulating Esr1 levels since ESR2 is known to significantly reduce the stimulatory 
effect of ESR1, thus inhibiting ESR1-mediated gene transcription (Hall and McDonnell, 1999; 
Lindberg et al., 2003).  
 We also found that Esr2 mRNA levels were induced significantly in controls compared 
to ESR1 OE antral follicles treated with 10 µg/ml MXC, but not 100 µg/ml. Studies have shown 
that the ability of ESR2 to function as a transcriptional inhibitor or activator depends on the 
agonist concentration, implying that, at various concentrations, there may be completely different 
patterns of gene expression (Hall and McDonnell, 1999). It is possible that at 100 µg/ml, the 
binding of MXC to ESR2 results in an unstable ESR2 dimer-DNA complex that results in 
inhibition of gene transcription, whereas at 10 µg/ml, MXC results in Esr2 gene transcription. 
Additionally, studies have shown that estrogenic chemicals exhibit differential effects on the two 
ESRs due to the differences in recruiting co-activators (Kuiper et al., 1998). ESR2 has been 
shown to retain a better ability to associate with co-activators when bound to xenoestrogens than 
when bound to estradiol (Kuiper G et al., 1998;Lemaire G et al., 2006), thus leading to increased 
gene transcription when exposed to environmental estrogens such as MXC. In our study, since 
control follicles have higher levels of ESR2 than ESR1, MXC could be binding predominantly to 
ESR2 and causing an increase in gene transcription resulting in higher levels of Esr2 mRNA. 
Our results showing that HPTE induces Esr2 expression in controls and ESR1 OE antral follicles 
are consistent with previous findings showing that HPTE treatment induces Esr2 levels in the 
ovary attributing it to an estrogen-like response (Waters, et al., 2001). We think that MOH 
induces Esr2 in ESR1 OE antral follicles in a similar way. 
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The dose-dependent increase in Ar expression levels in ESR1 OE and control follicles 
could be because MXC can bind to AR (Gaido et al., 2000), and may be inducing gene 
transcription increasingly with dose. However, in ESR1 OE antral follicles treated with 100 
µg/ml MXC, there is also a considerable induction of Esr1 which could possibly result in cross-
talk and subsequent higher expression of Ar in ESR1 OE follicles compared to control follicles.  
In ESR1 OE antral follicles, MXC treatment does not cause an alteration in Pr expression 
levels whereas, in control antral follicles, there is a significant induction of Pr at higher 
concentrations of MXC. It is possible that MXC may be directly binding to PR and inducing 
gene transcription at higher concentrations (Scippo et al., 2004). This may also explain the low 
levels of Esr1 and Esr2 mRNA at 100 µg/ml MXC in control antral follicles because there is 
evidence that activation of PR has an inhibitory effect on gene transcription by ESRs (Kraus WL 
et al., 1995).  
Both MOH and HPTE down regulate Ahr at their highest dose (10 µg/ml) in control and 
ESR1 OE antral follicles. There is substantial evidence of cross-talk between ESRs and AhR in 
various tissues including the ovary (Safe and Wormke, 2003). Studies have shown that TCDD-
induced activation of AhR results in down-regulation of ESRs (Krishnan et al., 1995). Hence, it 
is possible that the up-regulation of Esr2 by MOH and HPTE may be down-regulating Ahr in 
control and ESR1 OE antral follicles. 
Previous studies have shown that MXC treatment alters various CYP450 enzymes 
including Cyp1a2 and Cyp2c29 in the liver and ovary (Oropeza-Hernadez et al., 2003;Symonds 
et al., 2006). Moreover, ESR1 expression can also regulate certain CYP450 enzymes (Mwinyi et 
al., 2010) and hence it is possible that overexpression of ESR1 in ESR1 OE antral follicles is 
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altering gene transcription of Cyp1a2 and Cyp2c29 as well. Interestingly, when we analyzed 
Cyp3a41a, which is the enzyme responsible for metabolizing MOH and HPTE in ESR1 OE and 
control follicles treated with the chemicals, we observed a significant decrease of Cyp3a41a 
enzyme in DMSO treated ESR1 OE follicles compared to control follicles. This led us to analyze 
the levels of the metabolizing enzymes in the liver of adult cycling ESR1 OE and control female 
mice. While there were no changes in gene expression levels of Cyp1a2 and Cyp2c29 in the 
liver, we observed a significant decrease in Cyp3a41a mRNA in ESR1 OE antral follicles but not 
in control follicles. This suggests that the metabolism of MOH and HPTE in ESR1 OE mice is 
slower than controls, which could also explain the increased sensitivity of ESR1 OE mouse 
ovaries to MXC compared to controls (Tomic et al., 2006). 
In conclusion, several factors play a role in the interaction of ESR1 and ESR2 with 
different ligands and response elements as well as recruitment of distinct co-regulators, all of 
which collectively account for the differences in gene expression in control and ESR1 OE 
ovaries (Sanchez et al., 2002). This differential gene expression may account for the increased 
sensitivity of ESR1 OE antral follicles to toxicity induced by MXC and its metabolites. 
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3.6 Figures and Legends 
 
Figure 3.1 
 
 
 
 
 
 
 
 
 
 
 
Effect of MXC on the growth of antral follicles from controls and ESR1 OE mice in vitro. Antral 
follicles were cultured with either the vehicle DMSO or MXC (1-100 µg/ml). The graph 
represents growth of antral follicles after 96 h of culture and plotted as percent change from time 
0h.  A no-treatment (NT) group was included in each experiment as a control for culture 
condition. Each bar represents means ± SE. Asterisks (*) indicate statistically significant 
differences from controls (n = 13 -15 follicles per treatment from three separate experiments; 
p≤0.05). 
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Figure 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of MOH on the growth of antral follicles from controls and ESR1 OE mice in vitro. Antral 
follicles were cultured with either the vehicle DMSO or 0.1-10 µg/ml MOH. The graph 
represents growth of antral follicles after 96 h of culture and plotted as percent change from time 
0h.  A no-treatment (NT) group was included in each experiment as a control for culture 
condition. Each bar represents means ± SE. Asterisks (*) indicate statistically significant 
differences from controls (n = 13 -15 follicles per treatment from three separate experiments; 
p≤0.05). 
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Figure 3.3 
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Effect of HPTE on the growth of antral follicles from controls and ESR1 OE mice in vitro. 
Antral follicles from control (top panel) and ESR1 OE (bottom panel) mice were cultured with 
either the vehicle DMSO or 0.1-10 µg/ml HPTE treatments. The graph represents growth of 
antral follicles after 48, 72 and 96 h of culture and plotted as percent change from time 0h. A no-
treatment (NT) group was included in each experiment as a control for culture condition. Each 
bar represents means ± SE. Asterisks (*) indicate statistically significant differences from 
controls (n = 13 -15 follicles per treatment from three separate experiments; p≤0.05) 
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Figure 3.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of MXC, MOH and HPTE on gene expression levels of Esr1 in antral follicles of control 
and ESR1 OE mice in vitro. The relative gene expression quantities of Esr1 were normalized to 
β-Actin. (A) MXC (1-100 µg/ml) treated control follicles (left panel) and ESR1 OE follicles 
(right panel); (B) MOH (0.1-10 µg/ml) treated follicles; (C) HPTE (0.1-10 µg/ml) treated 
follicles. Each bar represents means ± SEM. Asterisks (*) indicate significant differences from 
DMSO controls within genotype. Bars with different letters are significantly different from each 
other (n = 13 -15 follicles per treatment from three separate experiments; p≤0.05). 
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Figure 3.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of MXC, MOH and HPTE on gene expression levels of Esr2 in antral follicles of control 
and ESR1 OE mice in vitro. The relative gene expression quantities of Esr2 were normalized to 
β-Actin. (A) MXC (1-100 µg/ml) treated follicles; (B) MOH (0.1-10 µg/ml) treated follicles; (C) 
HPTE (0.1-10 µg/ml) treated follicles. Each bar represents means ± SEM. Asterisks (*) indicate 
significant differences from DMSO controls within genotype. (n = 13 -15 follicles per treatment 
from three separate experiments; p≤0.05). 
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Figure 3.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of MXC, MOH and HPTE on gene expression levels of Ar in antral follicles of control 
and ESR1 OE mice in vitro. The relative gene expression quantities of Ar were normalized to β-
actin. (A) MXC (1-100 µg/ml) treated follicles; (B) MOH (0.1-10 µg/ml) treated follicles; (C) 
HPTE (0.1-10 µg/ml) treated follicles. Each bar represents means ± SEM. Bars with different 
letters are significantly different from each other (n = 13 -15 follicles per treatment from three 
separate experiments; p≤0.05). 
 
 
 
  
 59 
Figure 3.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of MXC, MOH and HPTE on gene expression levels of Pr in antral follicles of control 
and ESR1 OE mice in vitro. The relative gene expression quantities of Pr were normalized to β-
Actin. (A) MXC (1-100 µg/ml) treated follicles; (B) MOH (0.1-10 µg/ml) treated follicles; (C) 
HPTE (0.1-10 µg/ml) treated follicles. Each bar represents means ± SEM. Bars with different 
letters are significantly different from each other (n = 13 -15 follicles per treatment from three 
separate experiments; p≤0.05). 
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Figure 3.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of MXC, MOH and HPTE on gene expression levels of Ahr in antral follicles of control 
and ESR1 OE mice in vitro. The relative gene expression quantities of Ahr were normalized to β-
Actin. (A) MXC (1-100 µg/ml) treated follicles; (B) MOH (0.1-10 µg/ml) treated follicles; (C) 
HPTE (0.1-10 µg/ml) treated follicles. Each bar represents means ± SEM. Asterisks (*) indicate 
significant differences from DMSO controls within genotype. (n = 13 -15 follicles per treatment 
from three separate experiments; p≤0.05). 
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Figure 3.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of MXC, MOH and HPTE on gene expression levels of Cyp1a2 in antral follicles of 
control and ESR1 OE mice in vitro. The relative gene expression quantities of Cyp1a2 were 
normalized to β-Actin. (A) MXC (1-100 µg/ml) treated follicles; (B) MOH (0.1-10 µg/ml) 
treated follicles; (C) HPTE (0.1-10 µg/ml) treated follicles. Each bar represents means ± SEM. 
Bars with different letters are significantly different from each other (n = 13 -15 follicles per 
treatment from three separate experiments; p≤0.05). 
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Figure 3.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of MXC, MOH and HPTE on gene expression levels of Cyp2c29 in antral follicles of 
control and ESR1 OE mice in vitro. The relative gene expression quantities of Cyp2c29 were 
normalized to β-Actin. (A) MXC (1-100 µg/ml) treated follicles; (B) MOH (0.1-10 µg/ml) 
treated follicles; (C) HPTE (0.1-10 µg/ml) treated follicles. Each bar represents means ± SEM. 
Bars with different letters are significantly different from each other (n = 13 -15 follicles per 
treatment from three separate experiments; p≤0.05). 
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Figure 3.11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of MXC, MOH and HPTE on gene expression levels of Cyp3a41a in antral follicles of 
control and ESR1 OE mice. Antral follicles were cultured with MOH (0.1-10 µg/ml), HPTE 
(0.1-10 µg/ml) or the vehicle DMSO for 96h and then subjected to q-PCR with Cyp3a41a 
specific primers. The relative gene expression quantities of Cyp3a41a were normalized to β-
Actin. (A) MOH treated follicles; (B) HPTE treated follicles. Each bar represents means ± SEM. 
Bars with different letters are significantly different from each other (n = 13 -15 follicles per 
treatment from three separate experiments; p≤0.05). 
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Figure 3.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene expression levels of Cyp1a2, Cyp2c29 and Cyp3a41a (enzymes metabolizing MXC, MOH 
and HPTE) in livers of ESR1 OE and control mice. Sections of the lower lobe of the livers from 
adult female ESR1 OE and control mice were isolated and subjected to real-time PCR using 
specific primers for Cyp1a2, Cyp2c29 and Cyp3a41a. (A) Cyp1a2; (B) Cyp2c29; (C) Cyp3a41a 
mRNA levels. Each bar represents means ± SEM. Asterisk (*) indicates significant differences 
within genotype (n = 3; p≤0.05). 
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Table 3.1 Sequences of primer sets used for analysis of gene expression.  
 
 
Accession 
number 
 
Gene name Gene nomenclature Forward Reverse 
NM_007956 
Estrogen 
receptor 
alpha 
Esr1 
5'-
GTGCTTCAACATTCTCCCT
CCTC-3' 
5'-
CCGTGTGCAATGACTATGC
C-3' 
NM_207707 Estrogen receptor beta Esr2 
5'-
GGAATCTCTTCCCAGCAG
CA-3' 
5'-
GGGACCACATTTTTGCACT
T-3' 
NM_013476 Androgen receptor Ar 
5'-
GGCGGTCCTTCACTAATGT
CAACT-3' 
5'-
GAGACTTGTGCATGCGGT
ACTCAT-3' 
NM_008829 Progesterone receptor Pr 
5'-
GCTTGCATGATCTTGTGAA
ACAGC-3' 
5'-
GGAAATTCCACAGCCAGT
GTCC-3' 
NM_013464 
Aryl 
hydrocarbon 
receptor 
Ahr 
5'-
TTCTTAGGCTCAGCGTCAG
CTA-3' 
5'-
GCAAATCCTGCCAGTCTCT
GAT-3' 
NM_009993 Cytochrome P450 1a2 Cyp1a2 
5'-
TGTTCCGCCCAGAGCGGTT
T-3' 
5'-
ACTTCCCACTTGGCCGGGA
T-3' 
NM_017396 Cytochrome P450 3a41a Cyp3a41a 
5'-
TGAGCTTTCTCAGTGTCTG
TACAGGTT-3' 
5'-
TGAGATGTGGATGGAGAT
GGTCCC-3' 
NM_007815 Cytochrome P450 2c29 Cyp2c29 
5'-
TTTCTGGCCCCTGCTGTGA
TGC-3' 
5'-
TGCTGGGTCTTGAGAGAA
GAGGGT-3' 
NM_007393 Mouse Beta-actin β-Actn 
5'-
GGGCACAGTGTGGGTGAC-
3' 
5'-
CTGGCACCACACCTTCTAC
-3' 
 
  
 66 
3.7 References 
Borgeest C, Symonds D, Mayer LP, Hoyer PB, and Flaws JA. 2002. Methoxychlor may cause 
ovarian follicular atresia and proliferation of the ovarian epithelium in the mouse. Toxicol Sci 
68:473-478. 
Bulger WH, Muccitelli RM, and Kupfer D. 1978. Studies on the in vivo and in vitro estrogenic 
activities of methoxychlor and its metabolites. Role of hepatic mono-oxygenase in 
methoxychlor activation. Biochem Pharmacol 27:2417-2423. 
Chang EC, Charn TH, Park SH, Helferich WG, Komm B, Katzenellenbogen JA, and 
Katzenellenbogen BS. 2008. Estrogen receptors alpha and beta as determinants of gene 
expression: Influence of ligand, dose, and chromatin binding. Mol Endocrinol 22:1032-1043. 
Couse JF, Davis VL, Hanson RB, Jefferson WN, McLachlan JA, Bullock BC, Newbold RR, 
and Korach KS. 1997a. Accelerated onset of uterine tumors in transgenic mice with aberrant 
expression of the estrogen receptor after neonatal exposure to diethylstilbestrol. Mol Carcinog 
19:236-242. 
Couse JF, Lindzey J, Grandien K, Gustafsson JA, and Korach KS. 1997b. Tissue distribution 
and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) 
messenger ribonucleic acid in the wild-type and ERα-knockout mouse. Endocrinology 
138:4613-4621. 
Cummings, A. 1997. Methoxychlor as a model for environmental estrogens. Crit Rev Toxicol 
27:367-379. 
 67 
Danzo BJ. 1997. Environmental xenobiotics may disrupt normal endocrine function by 
interfering with the binding of physiological ligands to steroid receptors and binding proteins. 
Environ Health Perspect 105:294-301. 
Gaido KW, Leonard LS, Maness SC, Hall JM, McDonnell DP, Saville B, and Safe S. 1999. 
Differential interaction of the methoxychlor metabolite 2,2-bis-(p-hydroxyphenyl)-1,1,1-
trichloroethane with estrogen receptors α and β. Endocrinology 140:5746-5753. 
Gaido KW, Maness SC, McDonnell DP, Dehal SS, Kupfer D, and Safe S. 2000. Interaction of 
methoxychlor and related compounds with estrogen receptor alpha and beta , and androgen 
receptor: structure-activity studies. Mol Pharmacol 58:852-858. 
Golovleva LA, Polyakova AB, Pertsova RN, and Finkelshtein ZI 1984. The fate of 
methoxychlor in soils and transformation by soil microorganisms. J Environ Health Sci  
19:523-538. 
Gray LE Jr, Ostby JS, Ferrell JM, Sigmon CR, and Goldman JM. 1988. Methoxychlor induces 
estrogen-like alterations of behavior and the reproductive tract in the female rat and hamster: 
effects on sex behavior, running wheel activity, and uterine morphology. Tox Appl Pharm 96, 
525-540. 
Gupta RK, Miller KP, Babus JK, and Flaws JA. 2006. Methoxychlor inhibits growth and 
induces atresia of antral follicles through an oxidative stress pathway. Toxicol. Sci. 93:382-389. 
Hall JM and McDonnell DP. 1999. The estrogen receptor b-isoform (ERb) of the human 
estrogen receptor modulates ERa transcriptional activity and is a key regulator of the cellular 
response to estrogens and antiestrogens. Endocrinology 140:5566-5578. 
 68 
Hirshfield, A.N. 1991. Development of follicles in the mammalian ovary. Int. Rev. Cytol 
124:43-101. 
Hsueh AJ, Adashi EY, Jones PB, and Welsh TH Jr. 1984. Hormonal regulation of the 
differentiation of cultured ovarian granulosa cells. Endocr Rev 5:76-127. 
Jefferson WN, Couse JF, Padilla-Banks E, Korach KS, and Newbold RR. 2002. Neonatal 
exposure to genistein induces estrogen receptor (ER) alpha expression and multioocyte 
follicles in the maturing mouse ovary: evidnce for ER beta-mediated and nonestrogenic 
actions. Biol Reprod 67:1285-1296. 
Kapoor IP, Metcalf RL, Nystrom RF, and Sangha GK. 1970. Comparative metabolism of 
methoxychlor, methiochlor, and DDT in mouse, insects, and in a model ecosystem. J Agric 
Food Chem 18:1145-1152. 
Kraus WL, Weis KE, and Katzenellenbogen BS. 1995. Inhibitory cross-talk between steroid 
hormone receptors: differential targeting of estrogen receptor in the repression of its 
transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol Cell Biol 
15:1847-1857. 
Krishnan V, Porter W, Santostefano M, Wang X, and Safe S. 1995. Molecular mechanism of 
inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) in MCF-7 cells. Mol Cell Biol 15:6710-6719. 
Kuiper G, Lemmen JG, Carlsson B, Corton JC, Safe S, Van Der Saag PT, Van Der Burg B, 
and Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen 
receptor b. Endocrinol 139, 4252-4263. 1998.  
 69 
Lemaire G, Mnif W, Mauvais P, Balaguer P, and Rahmani R. 2006. Activation of a and b 
estrogen receptors by persistent pesticides in reporter cell lines. Life Sci 79:1160-1169. 
Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson JA, and Ohlsson 
C. 2003. Estrogen receptor (ER)-beta reduces ER(alpha)-regulated gene transcription 
supporting a "Ying-Yang" relationship between ER alpha and ER beta in mice. Mol 
Endocrinol 17:203-208. 
Matthews J and Gustafsson JA. 2003. Estrogen signaling: a subtle balance between ER alpha 
and ER beta. Mol Int 3:281-292. 
Miller KP, Gupta RK, and Flaws JA. 2006. Methoxychlor metabolites may cause ovarian 
toxicity through estrogen-regulated pathways. Toxicol Sci 93:180-188. 
Miller KP, Gupta RK, Greenfeld CR, Babus JK, and Flaws JA. 2005. Methoxychlor directly 
affects ovarian antral follicle growth and atresia through Bcl-2- and Bax-mediated pathways. 
Toxicol Sci 88:213-221. 
Murdoch FE and Gorski J. 1991. The role of ligand in estrogen receptor regulation of gene 
expression. Mol Cell Endocrinol 78:C103-C108. 
Mwinyi J, Cavaco I, Pederson RS, Persson A, Burkhardt S, Mkrtchian S, and Ingelman-
Sundberg M. 2010. Regulation of CYP2C19 expression by estrogen receptor alpha: 
implications for estrogen-dependent inhibition of drug metabolism. Mol Pharmacol 78:886-
894. 
Oropeza-Hernadez LF, Lopez-Romero R, and Albores A. 2003. Hepatic CYP1A, 2B, 2C, 2E 
and 3A regulation by methoxychlor in male and female rats. Toxicol Lett 144:93-103. 
 70 
Patisaul HB, Whitten PL, and Young LJ. 1999. Regulation of estrogen receptor beta mRNA in 
the brain: opposite effects of 17beta-estradiol and the phytoestrogen, coumestrol. Mol Brain 
Res 67:165-171. 
Safe S and Wormke M. 2003. Inhibitory aryl hydrocarbon receptor-estrogen receptor alpha 
cross-talk and mechanisms of action. Chem Res Toxicol 16:807-816. 
Sanchez R, Nguyen D, Rocha W, White JH, and Mader S. 2002. Diversity in the mechanism of 
gene regulation by estrogen receptors. Bioessays 24:244-254. 
Scippo M-L, Argiris C, Van de Weerdt C, Muller M, Willemsen P, Martial J, and Maghuin-
Rogister G. 2004. Recombinant human estrogen, androgen and progesterone receptors for 
detection of potential endocrine disruptors. Anal Bioanal Chem 378:664-669. 
Stresser DM and Kupfer D. 1997. Catalytic characteristics of CYP3A4: Requirement for a 
phenolic function in ortho hydroxylation of estradiol and mono-O-demethylated methoxychlor. 
Biochem 36:2203-2210. 
Stresser DM and Kupfer D. 1998. Human cytochrome P450-catalyzed conversion of the 
proestrogenic pesticide methoxychlor into an estrogen. Role of CYP2C19 and CYP1A2 in O-
demethylation. Drug Metab Dispos 26:868-875. 
Symonds, DA, Miller KP, Tomic D, and Flaws JA. 2006. Effect of methoxychlor and estradiol 
on cytochrome p450 enzymes in the mouse ovarian surface epithelium. Toxicol Sci 89:510-
514. 
Tanaka Y, Sasaki M, Kaneuchi M, Fujimoto S, and Dahiya R. 2003. Estrogen receptor alpha 
polymorphisms and renal cell carcinoma - a possible risk. Mol Cell Endocrinol 202:109-116. 
 71 
Tee MK, Rogatsky I, Tzagaraski-Foster C, Cvoro A, An J, Christy RJ, Yamamoto KR, and 
Leitman DC. 2004. Estradiol and selective estrogen receptor modulators differentially regulate 
target genes with estrogen receptors alpha and beta. Mol Biol Cell 15:1262-1272. 
Tomic D, Frech MS, Babus JK, Gupta RK, Furth PA, Koos RD, and Flaws JA. 2006. 
Methoxychlor induces atresia of antral follicles in er{alpha}-overexpressing mice. Toxicol. Sci. 
93:196-204. 
Tomic D, Frech MS, Babus JK, Symonds D, Furth PA, Koos RD, and Flaws JA. 2007. Effects 
of ER alpha overexpression on female reproduction in mice. Reprod Toxicol 23:317-325. 
Waters KM, Safe S, and Gaido KW. 2001. Differential gene expression in response to 
methoxychlor and estradiol through ERα, ERβ, and AR in reproductive tissues of female mice. 
Toxicol Sci 63:47-56. 
 
 
 
 72 
 
 
CHAPTER IV 
 
Estrogen receptor alpha overexpressing mouse antral follicles are sensitive to atresia 
induced by methoxychlor and its metabolites 
 
4.1 Abstract 
MXC and its metabolites are known to cause atresia in antral follicles in vitro and in vivo. 
Since these chemicals act via ESR1, I hypothesized that ESR1 OE antral follicles will be more 
susceptible to toxicity induced by MXC and its metabolites. In the previous chapter, ESR1 OE 
mouse antral follicles have been shown to be more sensitive to growth inhibition induced by 
MXC and its metabolites compared to controls. Hence, in this chapter I have analyzed the 
sensitivity of ESR1 OE antral follicles to atresia induced by MXC and its metabolites in vitro 
and in vivo. For in vitro experiments antral follicles were treated with vehicle DMSO, MXC (1, 
10 and 100 µg/ml) or MOH and HPTE (0.1, 1 and 10 µg/ml) were used. Results indicate that 
ESR1 OE antral follicles treated with MXC (1-100 µg/ml) and controls treated with 100 µg/ml 
but not 1 and 10 µg/ml had significantly higher rating of atresia compared to DMSO treatment. 
ESR1 OE antral follicles treated with 1 and 10 µg/ml MOH and 10 µg/ml HPTE in vitro had 
significantly high rating of atresia, whereas in controls, significantly high atresia rating was seen 
only with 10 µg/ml MOH compared to DMSO treatment. Moreover, activity of the pro-apoptotic 
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factor, caspase-3 was higher in ESR1 OE antral follicles treated with all MXC treatments in 
vitro, but not in controls. In vivo treatments of ESR1 OE mice with MXC (8, 16, 32 and 64 
mg/kg/day) caused an increased percentage of atretic antral follicles with the highest dose 
compared to controls. Furthermore, pro-caspase-3 levels were found to be significantly lower in 
ESR1 OE ovaries treated with the highest dose of MXC, but not in controls, indicating cleavage 
of pro-caspase-3 to activated caspase-3 at this dose. 
 
4.2 Introduction 
 
The ovaries of a post-pubertal mammalian female are composed of follicles at different 
stages of maturity. The follicle is the structural and functional unit of the ovary as it contains the 
female germ cell also known as the oocyte (Hirshfield, 1991). The ovary is responsible for 
nurturing and facilitating the follicle through various stages of its development such as 
primordial, primary, pre-antral and antral stages, until it can release the oocyte for fertilization 
(Hirshfield, 1991; Richards et al., 1987; McGee and Hsueh, 2000). However, not all follicles 
endowed to the female are destined to survive and release the oocyte. By a mechanism that is 
largely unknown, a relatively small number of follicles are recruited from the initial pool to 
ovulate and release an oocyte, while the rest of the follicles undergo atresia (Hirshfield, 1991; 
Tilly, 1996). Atresia is a process of programmed cell death (apoptosis) that occurs naturally in 
the granulosa cells of the ovary at all stages of follicular development throughout the 
reproductive lifespan. During follicular growth and development, approximately 99% of follicles 
undergo atresia due to apoptosis of granulosa cells (Hirshfield, 1991). Hence, atresia remains a 
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prominent feature of ovarian function until all the follicles are exhausted, resulting in 
reproductive senescence (Hirshfield, 1991; Zuckerman, 1951; Telfer et al., 2005).  
As the number of follicles endowed to the female at birth is finite, it is critical that 
sufficient numbers of healthy follicles be available for ovulation for normal reproduction (Telfer 
et al., 2005; Byskov et al., 2005). However, environmental toxicants such as the organochlorine 
pesticide, methoxychlor (MXC) have been shown to inhibit antral follicular growth and increase 
antral follicle atresia in mouse ovaries (Miller et al., 2005; Borgeest et al., 2002b; Gupta et al., 
2006a). MXC specifically targets antral follicles thus, raising the concern that exposure to MXC 
could cause depletion of antral follicles in the ovary, leading to infertility and early menopause 
(Borgeest et al., 2002a; Borgeest et al., 2004; Swartz and Eroschenko, 1998). Early menopause 
is a concern because it has been associated with an increased risk of chronic diseases such as 
osteoporosis and cardiovascular disease (Gast et al., 2008; Bagur and Mautzlen, 1992).  
Previous studies have shown that MXC may induce ovarian toxicity via the estrogenic 
pathway. Studies have also shown that the metabolites of MXC, MOH and HPTE are more 
potent estrogenic compounds than MXC and that they can inhibit antral follicle growth and 
increase antral follicular atresia to a greater extent than MXC (Bulger et al., 1978; Miller et al., 
2006). Since MXC and its metabolites can bind to estrogen receptors alpha and beta (ESR1 and 
ESR2) (Gaido et al., 2000; Waters et al., 2001), I examined whether a disruption in the number 
of estrogen receptors in the ovary alters the response of the ovaries to toxicity induced by MXC 
and its metabolites. Hence, I tested the effects of MXC and its metabolites on a transgenic mouse 
model in which estrogen receptor alpha (ESR1) was overexpressed (ESR1 OE) in the ovaries. I 
hypothesized that ovaries overexpressing ESR1 are more sensitive to antral follicle toxicity 
induced by MXC and its metabolites. 
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In our previous study, I reported that antral follicles of ESR1 OE were more sensitive to 
growth inhibition induced by MXC and its metabolites in vitro compared to controls (Paulose et 
al., 2011). Disruption in the normal ratio of ESR1:ESR2 in ESR1 OE mouse ovaries may be 
critical in driving the sensitivity of the antral follicle to MXC and its metabolites. In this study, I 
evaluated whether ESR1 OE antral follicles are more sensitive to atresia caused by MXC and its 
metabolites than control follicles. To address this, I carried out in vivo and in vitro studies on 
control and ESR1 OE mice as well as analyzed the levels of key players in the apoptotic 
pathway, including B-cell lymphoma/leukemia protein-2 (Bcl-2), which is an anti-apoptotic 
factor, Bcl-2 associated X protein (Bax) and Bcl-2 interacting domain (Bid), which are pro-
apoptotic factors, cysteine aspartate-specific protease – 3 (Caspase-3), which is the final 
executioner of apoptosis and poly (ADP-ribose) polymerase (PARP), which is a substrate of 
cleaved caspase-3. 
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4.3 Materials and Methods 
 
Chemicals 
 MXC (99%) was purchased from Chemservice (West Chester, PA). For in vivo 
experiments, mice were dosed with 8, 16, 32 and 64 mg/kg/day. Four stock solutions of MXC 
were prepared by using sesame oil (SES; Thermo Fisher Scientific Inc., Rockford, IL) as the 
vehicle. The stock concentrations were 5mg/ml for 8 mg/kg/day dose, 10mg/ml for 16 
mg/kg/day dose, 20 mg/ml for 32 mg/kg/day and 40 mg/ml for 64 mg/kg/day dose mg/kg/day 
(Paulose T et al., 2011). To keep the doses constant, mice were administered 1.6 ml/kg of the 
stock solutions. 
For in vitro experiments, stock solutions of MXC, MOH and HPTE were prepared by 
dissolving in dimethylsulfoxide (DMSO) (Sigma, St. Louis, MO). MOH and HPTE (99%) were 
synthesized in Dr. Vincent Njar’s laboratory (University of Maryland, Baltimore now at Thomas 
Jefferson University, Philadelphia, PA). MXC stock solutions were prepared by dissolving 1.33, 
13.3 and 133 mg/ml, while MOH and HPTE stock solutions were prepared by dissolving 0.133, 
1.3 and 13.3 mg/ml, resulting in a final concentration of 0.1, 1 and 10 µg/ml per well. The doses 
selected for the in vitro and in vivo studies were based on previously published studies showing 
that these concentration cause increased antral follicle atresia and inhibition of antral follicle 
growth in CD-1 mice. 
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Animals 
 ESR1 OE and control mice (32-39 day old cycling females) that were used in this study 
were generated using C57BL6 and FVB mice as described previously (Tomic et al., 2007; 
Paulose et al., 2011). ESR1 OE mice were validated for the overexpression of ESR1 gene and 
protein levels in the ovaries by quantitative real-time polymerase chain reaction (qPCR) and 
immunohistochemical staining techniques.  
 The mice were housed in the University of Illinois Veterinary Medicine core animal 
facility under a 12:12 dark:light cycle and provided food and water ad libitum. The University of 
Illinois Institutional Animal Care and Use Committee approved all animal procedures used in 
this study. 
 
In vivo dosing regimen 
 ESR1 OE and control were administered either sesame oil or MXC intraperitoneally 
using a 1 ml syringe at 1.6 ml/kg body weight. The doses were adjusted based on the animal’s 
most recent body weight. The mice were dosed continuously for a period of 20 days, as previous 
studies have shown that this length of exposure does not cause overt toxicity, but does induce 
antral follicle atresia. In addition, to be consistent with previous studies and to minimize 
variability in results, intraperitoneal route of administration was used. After dosing, all samples 
were collected when the mice were in estrus to decrease variability at various days of the estrous 
cycle and also because previous results have shown that MXC causes persistent estrus. 
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Antral follicle culture 
Antral follicles (determined by appearance and relative size) were isolated from ESR1 
OE and control ovaries using fine watchmaker forceps. About 75-80 antral follicles (300-400 
µm) were obtained from at least two mice of each genotype per experiment. The follicles were 
then randomly divided into five groups – non-treatment (NT), vehicle-control (DMSO) and three 
chemical treatments of MXC, MOH or HPTE. Increasing concentrations (1.33, 13.3 and 133 
mg/ml) of MXC and (0.133, 1.33 and 13.3 mg/ml) of MOH and HPTE were made to allow an 
equal volume to be added to each of the treatment groups in the 96-well culture plate to control 
the solvent concentration. The final concentrations of MXC in each well of the culture were 1, 10 
and 100 µg/ml. Similarly, final concentrations of MOH and HPTE in culture were 0.1, 1, and 10 
µg/ml. MOH and HPTE were used at 10-fold lower concentrations than MXC because the 
metabolites of MXC are thought to be more toxic than the parent compound. Moreover, the 
amount of the metabolites reaching the follicles after MXC has been metabolized is likely to be 
lower than the parent compound. In the vehicle control treatment group, DMSO was used at 
0.075%, which is not toxic to cultured follicles. The doses selected for in vitro studies were 
based on previously published studies showing that these concentrations of MXC, MOH and 
HPTE induce toxicity in antral follicles and granulosa cell culture models (Miller et al., 2005; 
Gupta RK et al., 2006a) A non-treatment group was included to control for culture conditions 
and follicles in this group were placed only in supplemented α-MEM devoid of either DMSO or 
chemicals.  
The follicles were cultured in supplemented α-MEM as described previously. Briefly, 
supplemented α-MEM was prepared using 1% ITS (10 ng/ml insulin, 5.5 ng/ml transferrin, 5.5 
ng/ml selenium), 100 U/ml penicillin, 100 mg/ml streptomycin, 5 IU/ml human recombinant 
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follicle-stimulating hormone (FSH; Dr. A. F. Parlow, National Hormone and Peptide Program, 
Harbor- UCLA Medical Center, Torrance, CA), and 5% fetal calf serum (Atlanta Biologicals, 
Lawrenceville, GA). Follicles were incubated for 96 hrs at 37°C in 95% air and 5% CO2.  
 
Histological evaluation of atresia 
 For the in vivo study, the ovaries of the mice in estrus were collected and fixed in 
Dietrick’s fixative. After fixation, the ovaries were dehydrated and embedded in Paraplast (VWR 
scientific, West Chester, PA), serially sectioned at 8 µm and stained with Weigert’s hematoxylin-
picric acid methyl blue. Follicles were classified as antral if they contained five or more layers of 
granulosa cells and a clearly defined antral space. Antral follicles were classified as atretic if 
10% of the granulosa cells were apoptotic (defined by the presence of pyknotic bodies in the 
granulosa cell layer), the granulosa cells were disorganized or the oocyte was fragmented or 
degenerating. 
 For evaluation of atresia in antral follicle cultures, the antral follicles exposed to DMSO 
or MXC/MOH/HPTE were fixed for at least 24 h in Dietrick’s fixative at the end of the culture. 
After a series of washes, the follicles were embedded in plastic (Technovit 7100), sectioned at 
2µm, and stained using Lee’s methylene blue - basic fuchsin. The amount of follicular atresia 
was examined in each antral follicle by the presence of pyknotic (apoptotic) bodies. Follicles 
were scored as healthy or atretic using a scale of 1-4 (1=healthy follicle; 2=10% apoptotic 
bodies/per follicle meaning an early atretic follicle; 3=10-30% of apoptotic bodies/per follicle 
meaning a mid atretic follicle; 4=greater than 30% apoptotic bodies/per follicle meaning a late 
atretic follicle). All scoring was done without knowledge of genotype or treatment group. At 
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least 2-3 antral follicles from three separate cultures were analyzed for atresia from each 
treatment group. 
 
Caspase activity 
 Caspase activity levels were analyzed in antral follicles that were exposed to DMSO or 
MXC in vitro using the Caspase-Glo 3/7 Assay (Promega Corporation, Madison, WI). The 
Caspase-Glo 3/7 Assay is a homogeneous, luminescent assay that measures caspase-3 and -7 
activities. Antral follicles were cultured with DMSO or MXC as described earlier. At the end of 
96 hours, the antral follicle from each well and the 100 µl of the supplemented media were 
placed into a white 96-well plate. As per manufacturer’s protocol, the reagents in the assay kit 
were mixed and added into each well containing the antral follicle in the supplemented media. 
The addition of the reagents in the assay kit results in cell lysis of the antral follicle, followed by 
the generation of a luminescent signal produced by luciferase. Luminescence is proportional to 
the amount of caspase activity present and was measured using a microplate reader with 
chemiluminescent filters. 
 
Western Blotting 
 Protein analyses of pro-caspase-3 and PARP1 were carried out using ovaries from control 
and ESR1 OE mice that were treated with vehicle or MXC in vivo. Antral follicles from an ovary 
were isolated and homogenized using 250 µl T-Per (Thermo Fisher Scientific, Rockford, IL) 
containing protease inhibitors (Roche Diagnostics, Mannheim, Germany). After homogenization, 
the protein concentration in the lysate was determined by using a bicinchoninic acid (BCA) assay 
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kit (Thermo Fisher Scientific, Rockford, IL). Electrophoresis and blotting was performed using 
reagents and XCell SureLock Mini-Cell Blot Module Kit (Invitrogen, Carlsbad, CA). The 
protein lysate (3-5µg) was loaded on a precast 4–12% Bis-Tris sodium dodecyl sulphate-
polyacrylamide gel (SDS-PAGE; Invitrogen, Carlsbad, CA), followed by wet transfer of the 
proteins to a blot at 4°C. The blot was incubated overnight at 4°C with primary antibodies, anti-
pro-caspase-3 and anti-PARP1 (1:1000; Cell Signaling Technologies, Danvers, MA), followed 
by incubation with secondary HRP-linked antibodies (1:2000) for 1 hour at room temperature. 
To ensure uniform loading of the proteins, the blot was stripped and incubated with anti-GAPDH 
(1:2000; EnCor Biotechnology Inc., Gainesville, FL), followed by incubation with an HRP-
linked secondary antibody. The immune complexes on the blot were visualized by using an 
enhanced chemiluminescence detection kit (Cell Signaling Technologies, Danvers, MA) and 
captured on X-ray film. Scanning densitometry using the Image J software downloaded from the 
NIH website (http://rsb.info.nih.gov/ij/) was used to compare the protein levels. Densitometric 
units of pro-caspase-3 were normalized to GAPDH for quantification. 
 
Gene analysis 
Gene expression analysis was carried out on antral follicles that were exposed to vehicle 
or MXC in vitro. Total RNA was extracted from follicles using the RNeasy Micro Kit (Qiagen, 
Inc., Valencia, CA) by homogenizing the follicles in buffer according to the manufacturer’s 
protocol. Total RNA (100-500 ng) from the follicles was then reverse transcribed to obtain 
complementary DNA (cDNA) using an iScript cDNA synthesis kit (Bio-Rad Laboratories, Inc., 
Hercules CA) according to the manufacturer’s protocol. Quantitative real-time (q-PCR) was 
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conducted using a CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., 
Hercules CA) and accompanying software according to the manufacturer's instructions. The 
machine quantifies the amount of q-PCR product generated by measuring the dye (SsoFast 
EvaGreen from Bio-Rad Laboratories, Inc., Hercules CA) that fluoresces when bound to double-
stranded DNA.  A standard curve was generated from five serial dilutions of purified q-PCR 
product. To detect genomic DNA contamination, a well containing total RNA was included each 
time. Gene-specific primers (synthesized by Integrated DNA Technologies, Inc., Coralville, 
Iowa) were used for the q-PCR (Table 1) and mouse β-actin was used as the reference gene. An 
initial incubation of 95°C for 10 min was followed by 40–50 cycles of 94°C for 10 s 
(denaturation step), 55°- 60°C (annealing step) for 10 s, and 72 °C for 10 s (extension step), 
along with a final extension at 72 °C for 10 min. Starting quantity (SQ), an arbitrary term 
generated by CFX96, denotes the relative gene expression level in the experimental samples. 
These values are calculated based on the standard curve and are read at the cycle at which the 
gene begins amplifying exponentially.  For each gene, a melting curve was performed at 55–
90 °C to monitor the generation of a single product. SQs from ESR1 OE and control samples 
were normalized by obtaining the ratio of gene:β-actin. The specificity of the primers was 
verified by the lack of amplification from genomic DNA and by a single melting curve. All 
experiments were performed in triplicate. 
 
Statistical analysis 
All data were analyzed using SPSS statistical software (SPSS, Inc., Chicago, IL). Data 
were expressed as means ± SEM from at least three separate experiments. Multiple comparisons 
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between experimental groups were done using analysis of variance (ANOVA) followed by 
Tukey's post hoc comparison. Comparison between two groups was done using Student’s t-test. 
Statistical significance was assigned at p≤0.05. 
 
4.4 Results 
 
Atresia caused by MXC in vivo 
Control and ESR1 OE mice were dosed with vehicle or MXC (8, 16, 32 and 64 
mg/kg/day) for a period of 20 days. The percentage of atretic antral follicles then was compared 
between sesame oil treated controls and MXC treated mice based on the presence of pyknotic 
bodies as shown in (Fig. 4.1A). The results indicate that in controls, all treatment groups had a 
significantly higher percentage of atretic antral follicles compared to sesame oil treated controls 
(Fig. 4.1B). Similarly, in ESR1 OE animals, all treatment groups had a significantly increased 
percentage of atretic antral follicles compared to sesame oil treated mice. Further, in ESR1 OE 
mice, the highest MXC treatment group (64 mg/kg/day) had a significantly higher percent of 
atretic antral follicles compared to any other treatment groups in both genotypes (Fig. 4.1B). 
Caspase-3 and PARP1 expression in MXC treated ovaries in vivo 
 Caspase-3 belongs to the cysteine aspartic acid-specific protease (caspase) family that has 
crucial effector functions in the apoptotic pathway in mammalian cells (Hsu and Hsueh, 2000). 
Pro-caspase-3 is cleaved to form active caspase-3 that targets and cleaves PARP1, driving the 
cells further into becoming apoptotic (Boone and Tsang, 1998; Fenwick and Hurst, 2002). 
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Hence, to analyze whether activation of pro-caspase-3 and PARP1 by MXC treatment in vivo is 
different in control and ESR1 OE mice, the antral follicles of the mice were subjected to western 
blot analysis of pro-caspase-3 and PARP1. PARP1 is a substrate of activated caspase-3 and 
cleaves it to form an 89 KDa cleaved PARP1 product.  
 The results indicate that in control mice, levels of pro-caspase-3 were not different in 
MXC treated ovaries compared to sesame oil treated mice (Fig. 4.2A top left panel). However, in 
ESR1 OE mice, pro-caspase-3 levels were significantly decreased in ovaries from MXC 64 
mg/kg/day treatment compared to sesame oil treatment (Fig. 4.2A top right panel).  
Densitometric analysis of pro-caspase-3 normalized to GAPDH was quantified as fold change 
over vehicle treatment (Fig. 4.2B). The results indicate that in controls, there was no difference 
in the levels of pro-caspase-3 protein, but in ESR1 OE ovaries, levels of pro-caspase-3 were 
significantly reduced in MXC 64 mg/kg/day treatment compared to sesame oil treated controls. 
To analyze if pro-caspase-3 was getting cleaved and activated, PARP1 levels were analyzed in 
control and ESR1 OE mice. Cleaved PARP1 expression was found in all the ovaries of controls 
and ESR1 OE mice treated with MXC and sesame oil (Fig. 4.2A middle panels). GAPDH levels 
were not different in ovaries of control or ESR1 OE mice across treatment groups (Fig. 4.2A 
bottom panels).  
Atresia caused by MXC and its metabolites in vitro 
 Antral follicles from control and ESR1 OE were isolated and cultured with MXC, MOH, 
HPTE or DMSO for 96 hours and rated for atresia (Fig. 4.3 A). The results indicate that antral 
follicles from control mice had a significantly higher rating of atresia in MXC 10 and 100 µg/ml 
treatment groups compared to DMSO treatment. However, in ESR1 OE antral follicles, the 
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atresia rating was higher in MXC 1, 10 and 100 µg/ml treatments compared DMSO treated 
follicles (Fig. 4.3B). Further, with MOH treatment, control antral follicles that were treated with 
MOH 10 µg/ml had significantly higher atresia rating compared to DMSO treatment. However, 
in ESR1 OE antral follicles, MOH 1 and 10 µg/ml had significantly higher ratings of atresia 
compared to DMSO treatment. Interestingly, ESR1 OE antral follicles treated with MOH 1 
µg/ml had a significantly higher atresia rating than controls treated with the same concentration 
of MOH (Fig. 4.3C). With HPTE treatment, the atresia rating in control antral follicles was not 
different between treatment groups and DMSO treated follicles. However, in ESR1 OE antral 
follicles, HPTE 10 µg/ml caused a significantly higher atresia rating compared to DMSO 
treatment (Fig. 4.3D).  
Caspase-3/7 activity in antral follicles treated with MXC in vitro 
 Caspase-3 and 7 are the main effector molecules in the caspase cascade leading to 
apoptosis (Johnson and Bridgham, 2002). Hence, the enzyme activity of caspase-3/7 was 
analyzed in antral follicles treated with vehicle or MXC in vitro. The results indicate that in 
controls, significantly high levels of caspase-3/7 activity were found in MXC 100 µg/ml 
treatment compared to DMSO treatment groups. However, in ESR1 OE antral follicles, 
significantly high caspase-3 activity levels were found in MXC 1, 10 and 100 µg/ml compared to 
DMSO treatment (Fig 4.4).  
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Gene expression levels of pro- and anti-apoptotic factors in antral follicles treated with MXC 
in vitro 
 To analyze the levels of pro-apoptotic factors, Bax and Bid, and the anti-apoptotic factor, 
Bcl-2, cultured antral follicles from control and ESR1 OE mice were subjected to qPCR. The 
results indicated that, in control antral follicles, mRNA levels of Bax were not different between 
treatment groups. However, in ESR1 OE antral follicles, Bax was significantly upregulated in 
MXC (100 µg/ml) compared to DMSO treatment (Fig. 4.5A). Gene expression analysis of Bid 
revealed that mRNA levels of Bid were significantly upregulated in controls treated with MXC 
100 µg/ml compared to DMSO treatment. Interestingly, in ESR1 OE antral follicles, mRNA 
levels of Bid were significantly higher in MXC 10 and 100 µg/ml compared to DMSO 
treatments (Fig. 4.5B). Gene expression levels of the anti-apoptotic factor Bcl-2 was not altered 
between treatment groups of control antral follicles, but was up-regulated significantly in ESR1 
OE antral follicles with MXC 100 µg/ml (Fig. 4.5C). 
 
4.5 Discussion 
 
 The ovary is a dynamic tissue, which consists of follicles that are continuously going 
through phases of growth and atresia. However, increased atresia could result in the depletion of 
the finite number of antral follicles in the ovary available for ovulation (Hirshfield, 1991). 
Excessive atresia may be induced as a result of toxic injury by estrogenic chemicals such as 
MXC and its metabolites. Previous studies have shown that MXC and its metabolites increase 
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atresia of mouse antral follicles in vivo and in vitro (Borgeest et al., 2002b; Miller et al., 2005). 
Since it is well known that MXC and its metabolites act via estrogen receptors, ovarian cells that 
have disrupted levels of estrogen receptors may respond differently to MXC and its metabolites 
compared to the normal ovary. In this study I used ESR1 OE mice that overexpress ESR1 in the 
theca cells of the ovary (Tomic et al., 2007). In the normal ovary, levels of ESR2 are higher than 
ESR1 since ESR2 is present in granulosa cells, which are abundant compared to theca cells. 
Many studies have shown that in tissues that co-express ESR1 and ESR2, the ratio of 
ESR1:ESR2 is critical for the response of the tissue to environmental estrogens (Chang et al., 
2008; Hall and McDonnell, 1999). Hence, I hypothesized that the ovaries of ESR1 OE mice will 
be more sensitive to toxicity induced by MXC and its metabolites since they can bind to more 
receptor sites. To address this, in the present study I dosed controls and ESR1 OE mice with 
increasing doses of MXC (8, 16, 32 and 64 mg/kg/day). Our results show that at 8, 16 and 32 
mg/kg/day MXC doses, controls and ESR1 OE mice have an increased percentage of atretic 
antral follicles compared to sesame oil treated mice.  However, consistent with our previous 
results, at 64 mg/kg/day MXC dose, ESR1 OE mice have a significantly higher percentage of 
atretic antral follicles compared to other treatment groups of both genotypes (Tomic et al., 2006).  
To test our hypothesis using a direct approach, I also conducted in vitro studies to 
evaluate the levels of atresia in ESR1 OE and control antral follicles using MXC and its 
metabolites. As opposed to the in vivo study, where I could not control the amounts of MXC 
reaching the ovaries, in the in vitro experiments, individual antral follicles were isolated and 
treated with various concentrations of MXC, MOH and HPTE directly. The results indicate that 
control mice treated with 10 and 100 µg/ml MXC have a significantly increased atresia rating 
compared to 1 µg/ml and DMSO treated follicles. However, ESR1 OE antral follicles have 
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significantly higher levels of atresia at 1, 10 and 100 µg/ml compared to DMSO treatment, 
indicating an increased sensitivity of ESR1 OE antral follicles to the lowest dose of MXC 
compared to control follicles.  With MOH treatment, control antral follicles were significantly 
atretic at the highest dose of 10 µg/ml MOH compared to DMSO treatment. Interestingly, in 
ESR1 OE, 1 and 10 µg/ml of MOH significantly increased the atresia rating compared to DMSO 
treatment. With HPTE treatment, atresia was not induced in controls by any of the treatments. 
However, in ESR1 OE antral follicles, 10 µg/ml HPTE significantly increased the atresia rating 
compared to DMSO treatment. Collectively, these results indicate that ESR1 OE antral follicles 
are more sensitive to atresia induced by MXC in vivo and in vitro and more sensitive to MOH 
and HPTE in vitro compared to controls.  
Since apoptosis is the molecular basis of atresia, it is important to evaluate the levels of 
apoptotic factors that may cause the increased sensitivity of ESR1 OE to MXC compared to 
controls (Tilly, 1996). Previous studies have shown that MXC increases oxidative stress in the 
ovaries and that it causes mitochondrial dysfunction (Gupta et al., 2006a; Gupta et al., 2006b). 
This is a likely trigger for apoptosis, as increased production of hydrogen peroxide in the cells is 
known to cause apoptosis.  Apart from this, previous studies have shown that MXC causes an 
increase in Bax in the ovaries, whereas mice that overexpress Bcl-2 are protected from MXC 
induced atresia (Borgeest et al., 2004; Miller et al., 2005). Increased oxidative stress and 
increased Bax production followed by mitochondrial dysfunctioning are all key factors that can 
activate the apoptotic pathway by causing an alteration in the mitochondrial inner 
transmembrane potential. This results in the formation of a conductance channel known as the 
mitochondrial permeability transition pore, through which cytochrome c is released. Cytochrome 
c complexes with Apaf-1 and Caspase-9 to form an active apoptosome that can cleave pro 
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caspase-3 and 7. Once the mitochondrial pore is formed resulting in activation of caspases, an 
infinite loop is created, in which an increase in caspase activity results in increased 
mitochondrial permeability and vice-versa. Caspase-3 and 7 are known as effector caspases since 
they cleave critical proteins needed for maintaining homeostasis and disable vital processes 
essential for cell survival (Boone and Tsang, 1998). One of the key proteins cleaved by caspase-
3 is PARP-1, a key signaling enzyme and a prompt DNA damage sensor, involved in triggering 
single-strand DNA repair (Boone and Tsang, 1998). Cleavage of PARP-1 by caspase-3 disables 
it and drives the cell towards apoptosis (Johnson and Bridgham, 2002; Fenwick and Hurst, 
2002).  
In our present study, I analyzed the levels of caspase-3 protein in control and ESR1 OE 
antral follicles after in vivo treatment with MXC. The results showed that the protein levels of 
pro caspase-3 were significantly decreased in ESR1 OE mice treated with 100 mg/kg/day MXC 
compared to controls. I could not detect cleaved caspase-3 in my western blot, likely because of 
the small amount of protein loaded (5 µg) and the small size of the cleaved protein (17 KDa). 
However, as GAPDH levels were uniform in all treatment groups of controls and ESR1 OE, I am 
confident that the significant decrease in pro-caspase-3 in ESR1 OE ovaries treated with MXC 
64 mg/kg/day was indeed due to cleavage of the protein. Moreover, cleaved PARP1 was found 
in all treatment groups of controls and ESR1 OE, further confirming that active caspase-3 were 
present in these cells. However, levels of PARP1 were not different between treatment groups of 
either genotype, indicating that other targets of downstream caspase-3 signaling could also be 
involved in causing an increase in atresia in ESR1 OE antral follicles compared to controls. 
There were significantly high levels of caspase-3/7 activity in antral follicles that were 
treated in vitro with MXC compared to controls. Moreover, gene expression levels of the pro-
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apoptotic factor, Bax were not different between treatment groups in controls, while they were 
significantly higher in ESR1 OE antral follicles treated with MXC 100 µg/ml compared to 
DMSO treatment. Further, in controls, gene expression levels of pro-apoptotic factor Bid were 
significantly higher in 100 µg/ml MXC compared to DMSO treatment, whereas in ESR1 OE 
antral follicles, 10 and 100 µg/ml MXC had higher levels of Bid compared to DMSO treatment. 
Gene expression levels of the anti-apoptotic factor Bcl-2 were higher in antral follicles treated 
with MXC in both genotypes, possibly as an attempt to rescue the follicles. Collectively, the 
results from our in vitro studies indicate that the higher levels of caspase-3/7 activity in ESR1 
OE antral follicles treated with MXC compared to controls is possibly due to an increase in up-
stream pro-apoptotic factors such as Bax and Bid. Since caspase-3/7 is known as the final 
executioner of apoptosis, an up-regulation of its activity by MXC in ESR1 OE antral follicles 
will result in increased atresia compared to controls. 
In conclusion, this study has shown that ESR1 OE antral follicles are more sensitive to 
atresia induced by MXC and its metabolites compared to controls, as seen by histological 
analysis of antral follicles. As MXC, and not its metabolites, is the pesticide that is sprayed on 
fruits and vegetables, I thought it relevant to analyze the molecular signaling of apoptosis in 
antral follicles exposed to MXC. Hence, I have shown that anti-apoptotic factors, Bax, Bid and 
caspase-3/7 play crucial roles in mediating increased atresia in ESR1 OE antral follicles 
compared to controls. Future studies will include investigating other signaling molecules 
downstream of caspase-3/7, which are cleaved and activated, causing increased atresia in ESR1 
OE antral follicles compared to controls. 
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4.6 Figures and Legends 
 
Figure 4.1 
 
A 
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Evaluation of atresia in control and ESR1 OE ovaries treated in vivo with sesame oil (SES) or 
MXC (8 - 64 mg/kg/day). Ovaries of mice were collected and fixed for histological evaluation of 
atresia. (A) Histological sections of ovaries were analyzed for atresia by comparing the presence 
of apoptotic bodies. Representative sections of a healthy antral follicle (left panel) and an atretic 
antral follicle (right panel) with red arrows pointing to apoptotic bodies are shown. (B) The 
percentage of atretic antral follicles were quantified and plotted on a graph. Each bar represents 
means ± SEM. Bars with different letters are significantly different from each other (n = 6; 
p≤0.05) 
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Figure 4.2 
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Protein expression of pro-caspase-3 and PARP1 in control and ESR1 ovaries after 20 days of in 
vivo dosing with SES or MXC (8 – 64 mg/kg/day). (A) Ovaries of mice were collected and 
subjected to protein analysis by western blotting using specific antibodies for pro-caspase-3 (top 
panel), PARP1 (middle panel) and loading control, GAPDH (bottom panel). (B) Densitometric 
units of pro-caspase-3 bands normalized to GAPDH were quantified as fold change over SES in 
controls and ESR1 OE ovaries. Each bar represents means ± SEM. Asterisk (*) indicates 
significant difference from SES controls within genotype. (n = 3; p≤0.05). 
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Figure 4.3 
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Evaluation of atresia in control and ESR1 OE antral follicles treated in vitro with vehicle, DMSO 
or MXC, MOH, HPTE. (A) Histological sections of antral follicles were rated for atresia by 
comparing the presence of apoptotic bodies. Representative sections of a healthy antral follicle 
(top panel) and an atretic antral follicle (bottom panel) with black arrows pointing to apoptotic 
bodies are shown. (A) MXC (1-100 µg/ml) treated follicles; (B) MOH (0.1-10 µg/ml) treated 
follicles; (C) HPTE (0.1-10 µg/ml) treated follicles. Each bar represents means ± SEM. Asterisks 
(*) indicate significant differences from DMSO controls within genotype. (n = 2-3 follicles per 
treatment from three separate experiments; p≤0.05). 
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Caspase-3/7 activity measured in antral follicles treated in vitro with MXC (1-100 µg/ml) for 
96h. Antral follicles were treated with either DMSO or MXC for 96 h and treated with reagents 
in the Caspase-­‐Glo-­‐3/7assay	   kit.	   Luminescence	   is	   proportional	   to	   the	   amount	   of	   caspase	  activity	  present	  which	  was	  measured	  and	  plotted	  as	   fold	   change	  over	  DMSO	   treatment.	   . 
Each bar represents means ± SEM. Asterisks (*) indicate significant differences from DMSO 
controls within genotype. (n = 4-6 follicles per treatment from three separate experiments; 
p≤0.05). 	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Effect of MXC (1-100 µg/ml) on gene expression levels of pro and anti-apoptotic factors in 
antral follicles of control and ESR1 OE mice in vitro. The relative gene expression quantities of 
were normalized to β-Actn. (A) Gene expression levels of pro-apoptotic factor, Bax; (B) Gene 
expression levels of pro-apoptotic factor, Bid; (C) Gene expression levels of anti-apoptotic 
factor, Bcl-2. Each bar represents means ± SEM. Asterisks (*) indicate significant differences 
from DMSO controls within genotype. (n = 13 -15 follicles per treatment from three separate 
experiments; p≤0.05.) 
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Table 4.1 Sequences of primer sets used for analysis of gene expression.  
 
 
Accession 
number 
 
Gene name 
Gene 
nomenclature 
Forward Reverse 
NM_009741 
 
B-cell 
leukemia/lymphoma 
2 
 
Bcl-2 
5'-
ATGCCTTTGTGGAA
CTATATGGC-3' 
5'-
GGTATGCACCCAGA
GTGATGC-3' 
NM_007527 
 
BCL2-associated X 
protein 
 
Bax 
5'-
TGAAGACAGGGGC
CTTTTTG-3' 
5'-
AATTCGCCGGAGAC
ACTCG-3' 
NM_007544 
BH3 interacting 
domain death 
agonist 
Bid 
5'-
GCCGAGCACATCA
CAGACC-3' 
5'-
TGGCAATGTTGTGG
ATGATTTCT-3' 
NM_007393 Mouse Beta-actin β-Actn 
5'-
GGGCACAGTGTGG
GTGAC-3' 
5'-
CTGGCACCACACCT
TCTAC-3' 
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CHAPTER V 
 
Methoxychlor-induced ovarian follicle toxicity in mice: dose and exposure duration-
dependent effects 
 
5.1 Abstract 
The organochlorine pesticide MXC is known to cause ovarian toxicity and reduced 
fertility in mammals. Specifically, MXC is known to target antral follicles and increase atresia of 
antral follicles. This is of concern because females are born with a finite pool of follicles that can 
mature to ovulate during the reproductive years. However, there are limited studies that have 
explored whether there may be a threshold in the amount of antral follicle atresia, which could 
lead to reduced fertility. In this chapter, we dosed adult female CD-1 mice with various doses of 
MXC for 5, 10, 20 and 30 days. Significantly increased percentage (50%) of atretic antral 
follicles was only observed after 20 and 30 days of treatment. In the 20 day treatment, mice were 
dosed with the vehicle sesame oil, or MXC (64 or 96 mg/kg/day), while in the 30 day treatment, 
mice were dosed with sesame oil or MXC (48, 64, 96 mg/kg/day). Results indicate that treating 
mice with 64 mg/kg/day MXC for 20 and 30 days caused increased percent of atretic antral 
follicles compared to vehicle treated mice. Interestingly, mice dosed with 96 mg/kg/day MXC 
had increased percent of atretic antral follicles after 30 days of treatment but not after 20 days 
 102 
treatment compared to vehicle treated mice. The mice that were dosed with MXC (48 and 96 
mg/kg/day) for 30 days were also mated with untreated males to determine fertility of the treated 
mice. Results indicate that the mice did not manifest reduced fertility with these treatments 
compared to controls indicating that 50% atretic antral follicles did not affect immediate fertility 
of the mice. 
 
5.2 Introduction 
 
Methoxychlor (MXC), an organochlorine pesticide, has been well screened for its 
estrogenicity and for causing reproductive abnormalities in mammalian females (Cummings, 
1997; Gaido et al., 2000; Eroschenko et al., 1996; Gray et al., 1999; Miller et al., 2006). In the 
past, MXC was widely used around the world to prevent crops, fruits, and livestock from being 
attacked by insects and pests. Although the usage of MXC has ceased in the US, exposures may 
occur from fruits and vegetables imported to US markets from other countries that use MXC. 
Some of the adverse reproductive effects seen in female mice after treatment with MXC include 
premature vaginal opening, vaginal cornification, persistent estrus, ovarian atrophy, decreased 
ovulation and increased atresia of antral follicles (Borgeest et al., 2002; Gray et al., 1989; 
Eroschenko and Cooke, 1990).  
Several in vivo and in vitro studies have shown that MXC targets antral follicles 
specifically by inhibiting growth and increasing atresia of antral follicles in rodent ovaries 
(Swartz and Corkern, 1992; Martinez and Swartz, 1991; Gupta et al., 2006; Borgeest et al., 
2002). Follicle-targeted toxicity is common among ovarian toxicants, since several chemicals 
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have been shown to target specific follicle types in the ovary (Flaws et al., 1994; Burkl and 
Schiechl, 1978). While chemicals that target primordial follicles may cause permanent infertility 
because of the depletion of a finite number of growing follicles, chemicals such as MXC that 
target antral follicles may cause temporary infertility if the chemical is removed, but may also 
cause permanent infertility if the chemical is not removed (Hirshfield, 1997). MXC may also 
cause premature reproductive senescence as a result of increased follicle atresia. Premature 
reproductive senescence is a major concern in women because this may increase the risk of 
cardiovascular diseases, osteoporosis and hypertension (Bagur and Mautzlen, 1992; Ashraf and 
Vongpatanasin, 2006; Gast et al., 2008).  
In the past, studies have shown that in utero or neonatal exposure to MXC causes 
reproductive abnormalities, including increased atresia in antral follicles and reduced fertility 
that are manifested in the animal at adulthood (Swartz and Corkern, 1992; Swartz and 
Eroschenko, 1998). These findings suggest that exposure to MXC at critical periods of ovarian 
development may make the ovaries more sensitive to MXC induced toxicity later on as adults. 
However, there is limited knowledge about the effects of MXC in the adult mouse ovary at 
various low and high doses over several exposure periods. Moreover, there is also inadequate 
knowledge about whether increased follicular atresia caused by MXC in the ovaries reduces the 
immediate fertility of the female.  
Previously, studies have shown that 20-day exposure of MXC at 32 and 64 mg/kg/day 
significantly increased the percentage of atretic antral follicles in the ovary, but the same doses at 
a 10-day exposure did not increase atresia significantly (Borgeest et al., 2002). Hence, the 
question arises whether increased atresia of antral follicles would have short-term or long-term 
adverse effects in reproduction.  To address this question, we included a wide range of doses and 
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several exposure periods of MXC to determine the critical doses and window of exposure in 
adult female mice that can cause ovarian toxicity. Furthermore, we bred some of the female mice 
that were dosed with MXC to untreated males to determine whether MXC induced toxicity 
results in immediate impairment of female fertility. 
 
5.3 Materials and Methods 
 
Testing Facilities 
 This study was carried out in two parts. The first dosing regimen (Group A) was carried 
out for a period of 5 and 10 days at the University of Maryland, Baltimore, MD. The second 
dosing regimen (Group B) was carried out at Nucro-Technics, Scarborough, Ontario, Canada for 
a period of 20 and 30 days. 
 
Chemicals  
Group A – MXC (99%) was purchased from Chemservice (West Chester, PA). MXC was 
dissolved in sesame oil at 5, 10, 20, 40, 80 and 100 mg/ml for 8, 16, 32, 64, 128 and 160 
mg/kg/day doses. Group B – MXC (98%) was purchased from MP Biomedicals, LLC (Solon, 
OH) and dissolved in sesame oil at 15, 20 and 30 mg/ml for 48, 64, 96 mg/kg/day doses. 
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Animals 
 Group A – Cycling female CD-1 mice between ages 32 and 36 days were obtained from 
Charles River Laboratories (Wilmington, MA) and housed five animals per cage at the 
University of Maryland School of Medicine Central Animal Facility. Food and water were 
provided ad libitum and the mice were housed in a controlled animal room environment 
(temperatures 18 - 26°C, 12-h light-dark cycles). The University of Maryland School of 
Medicine Institutional Animal Use and Care Committee approved all testing procedures on the 
mice. Group B – 5-6 week old female and 8-9 week old male CD-1 mice were purchased from 
Charles River Inc. (Montreal, PQ, Canada). The mice were individually housed in rat/mouse 
cages at the testing facility, Nucro-Technics and provided food and water ad libitum throughout 
the study period. The mice were kept in a controlled animal room environment (temperatures 18 
- 26°C, 12-h light-dark cycles) and monitored daily according to Nucro-Technics Standard 
Operating Procedures. All animals used in the study were treated in accordance with the 
principles described in the current “Guide for the Care and Use of Experimental Animals as 
published by the Canadian Council on Animal Care. 
 
Dosing regimen 
Group A – The dosing regimen was carried out for 5 or 10 days of continuous exposure 
periods with 5-10 female mice per treatment group. In the 5-day dosing period, each mouse 
received the vehicle sesame oil (SES), 64, 128 or 160 mg/kg/day of MXC. In the 10-day dosing 
period, each mouse received either SES, 8, 16, 32, 64, 128 or 160 mg/kg/day of MXC. The mice 
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were administered either SES or MXC intraperitoneally using a 1 ml syringe at 1.6 ml/kg body 
weight. The doses were adjusted based on the animal’s most recent body weight. 
Group B – The dosing regimen was carried out with 10 female CD-1 mice per treatment 
group for 20 or 30 days of continuous exposure periods. In the 20-day dosing period, each mouse 
received either SES, 64 or 96 mg/kg/day of MXC. In the 30-day dosing period, each mouse 
received either SES, 48, 64 or 96 mg/kg/day of MXC. The mice were administered either SES or 
MXC intraperitoneally using a 23 G needle attached to a 1 ml syringe at 3.2 ml/kg body weight. 
The doses were adjusted based on the animal’s most recent body weight. 
 
Breeding and litter analysis 
CD-1 females in the 30-day dosing period of Group B were mated with untreated male 
CD-1 mice (1:1 ratio) for up to 7 days starting the day after cessation of dosing. The date of 
observation of the vaginal plug was recorded and considered gestational day (GD) 1. Starting on 
GD1, the female mice were weighed every 3-5 days to monitor pregnancy. On GD 17-19, 
pregnant dams were anesthetized by exposure to isoflurane and pups removed by cesarian 
section and weighed. The uterus was examined and the dams and pups were euthanized 
immediately by exposure to CO2/O2. After euthanasia, the ovaries of the dams were collected 
weighed and fixed in Dietrick’s fixative for histological processing. 
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Histological evaluation of atresia 
 After dosing, the ovaries of the mice were collected and fixed in Dietrick’s fixative. After 
fixation, the ovaries were dehydrated and embedded in Paraplast (VWR scientific, West Chester, 
PA), serially sectioned and stained for histological evaluation of atresia. Follicles were classified 
as antral if they contained five or more layers of granulosa cells and a clearly defined antral 
space. Antral follicles were classified as atretic if 10% of the granulosa cells were apoptotic 
(defined by the presence of pyknotic bodies in the granulosa cell layer), the granulosa cells were 
disorganized or the oocyte was fragmented or degenerating. 
 
Statistical analysis 
All data were analyzed using SPSS statistical software. For all comparisons, statistical 
significance was assigned at p ≤ 0.05. For comparisons between SES and MXC-treatment 
groups, analysis of variance was used followed by Tukey’s post-hoc test.  
 
5.4 Results 
 
Atresia caused by MXC in CD-1 mouse ovaries 
 CD-1 female mice were dosed intraperitoneally with either the vehicle (sesame oil) or 
varying doses of MXC (8 – 160 mg/kg/day) for 5, 10, 20 or 30 days. Treatment with 5d 
treatment of MXC (64, 128 and 160 mg/kg/day) did not significantly increase the percent atretic 
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antral follicles compared to vehicle control (Fig. 5.1). Treatment with MXC (8, 16, 32, 64, 128 
and 160 mg/kg/day) for 10 days did not cause a significant difference in percent atretic antral 
follicles between vehicle and MXC treated mice. However, there was a decrease in percent 
atretic antral follicles at 64 and 128 mg/kg/day compared to 8 and 160 mg/kg/day treatment 
groups (Fig. 5.2). Treatment with MXC (64 and 96 mg/kg/day) for 20 days significantly 
increased percent atretic antral follicles with 64 mg/kg/day MXC, but not with 96 mg/kg/day 
compared to vehicle treated mice (Fig. 5.3). Treatment with MXC (48, 64 and 96 mg/kg/day) for 
30d significantly increased percent atretic antral follicles at 64 and 96 mg/kg/day, but not 48 
mg/kg/day compared to vehicle treated mice (Fig. 5.4). 
 
Effect of MXC on breeding and ovarian weight 
 After 30 days of treatment with vehicle or MXC (48 and 96 mg/kg/day) and vehicle, the 
treated female CD-1 mice were mated with untreated sexually mature male CD-1 mice. The 
pregnant dams were euthanized on gestational day 17 – 19 and the fetuses were collected. The 
ovarian weights of the treated dams, the litter size and individual fetal weights were recorded. 
The ovarian weights of the dams treated with MXC were significantly lower than those of 
vehicle treated dams (Table 5.5). Overall there were no differences in the number of fetuses per 
litter of the treated dams compared to vehicle treated dams. However, one dead fetus and an 
early and late resorption were observed at the time of collection in MXC 64 group. There was 
one late resorption observed in MXC 96 group at the time of collection. 
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5.5 Discussion 
 Our present study provides a deeper insight into the dose of MXC that is critical for 
eliciting a biological response. In this study, we show that the dose as well as the duration of 
exposure determines the ability of MXC to increase atresia of antral follicles in the ovary. 
Specifically, when adult female CD-1 mice were exposed to MXC for five days, there were no 
differences in percent atretic antral follicles in the ovaries of vehicle or MXC treated mice. It is 
possible that the ovaries are able to tolerate an acute exposure of five days, and the toxicity of 
MXC is warded off by robust defense mechanisms in the body, including detoxification by the 
liver. Interestingly, even after ten days of exposure to MXC at doses ranging from 8 – 160 
mg/kg/day, there were no differences in percent atretic antral follicles between the vehicle and 
MXC treated mice. However, between treatment groups, it is noteworthy that the lowest dose (8 
mg/kg/day) and the highest dose (160 mg/kg/day) significantly increased percent atretic antral 
follicles compared to 64 and 128 mg/kg/day, suggesting a non-monotonic dose response curve 
for this exposure. 
 Previous studies have shown that when adult female CD-1 mice were treated with MXC 
at doses 8 – 32 mg/kg/day for 20 days, there was an increase in percent atretic antral follicles 
with 32 mg/kg/day compared to vehicle treatment (Borgeest et al., 2002). In this study, we 
extended the treatment regimen by including 64 and 96 mg/kg/day doses. Interestingly, we 
observed an increase in percent atretic antral follicles at 64 mg/kg/day, but not at 96 mg/kg/day 
suggesting non-monotonic dose response at this exposure period. Interestingly, at 30 days of 
exposure, 64 and 96 mg/kg/day, but not 48 mg/kg/day of MXC showed an increase in percent 
atretic antral follicles compared to vehicle treatment.  
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Although the reasons for non-monotonic dose-response as seen with exposure to MXC 
are unknown, there is a possible explanation based on a biochemical study on xenobiotic 
compounds (Kohn and Melnick, 2002). The U-shaped curves arise when normal levels of the 
endogenous ligand of the nuclear receptor are not sufficient to saturate the binding sites. 
Subsequently, xenobiotic compounds bind to hormone receptors, but the resulting DNA-
receptor-xenobiotic ligand complex is less stable than when the receptor is bound to the 
endogenous ligand, giving rise to non-monotonic dose response curves. Non-monotonic dose 
response curves are a common occurrence with estrogen and estrogenic compounds and have 
been a topic of interest among researchers over the past several years. Several studies have 
shown variable tissue responses with low versus high doses of estrogenic compounds in different 
tissues (Alworth et al., 2002; Newbold et al., 2004). Variable responses with low versus high 
doses of MXC have also been reported in a few studies. One such study has shown complete 
reversal of effects with low and high doses of MXC. In adult female rats that were exposed to 
MXC neonatally, estrous cyclicity started earlier in animals exposed to 25 mg/kg-day, at a 
normal age in animals exposed to 50-100 mg/kg-day, and was delayed in animals dosed with 200 
mg/kg-day (Gray et al., 1989). Similarly, in another study, lower doses of MXC in mice caused 
an increase in ovarian weight and numbers of corpora lutea, while higher doses caused ovarian 
atrophy and depletion of corpora lutea. Furthermore, follicular cysts were only recorded with the 
intermediate dose of MXC (Eroschenko et al., 1995). Our data suggest that at 20-day exposure, 
MXC causes an inverted U-shaped dose response in percent atretic antral follicles. 
 The decrease in ovary weights that we observed in this study is consistent wit,h previous 
studies showing the adverse effects of MXC in the female reproductive tract (Martinez and 
Swartz, 1991; Eroschenko et al., 1995). However, after breeding female mice that were dosed 
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with 48 and 96 mg/kg/day MXC for thirty days with untreated fertile males, we observed no 
differences in pups/litter compared to vehicle treatment. These data concur with previous 
observations that MXC targets antral follicles specifically (Martinez and Swartz, 1991; Borgeest 
et al., 2002). Hence, it is possible that once MXC is removed, the immature follicles are able to 
grow into antral follicles and recruit them for ovulation to replace the cohort of antral follicles 
that became atretic with MXC treatment. Alternatively, it is possible that some pre-ovulatory 
antral follicles escaped the toxic effects of MXC and were able to ovulate. In previous studies 
that have shown decreased fertility of mice after MXC treatment, the animals were treated in 
utero or neonatally (Swartz and Eroschenko, 1998; Swartz and Corkern, 1992). During 
developmental stages, MXC could be altering the blueprint of follicle development by causing a 
defect in the compensatory repair system of the cells that becomes evident only as adults at the 
time of reproduction. In our study, adult cycling CD-1 female mice that were dosed for 30 days 
and immediately mated with untreated adult males did not show decreased fertility compared to 
controls. It is possible that MXC acts at specific windows of development, which make the 
developing follicles more sensitive to toxicity induced by MXC, resulting in decreased fertility 
manifested during adulthood. Our present findings suggest that mice that have never been 
exposed to MXC during prenatal or neonatal development, but are exposed as adults, have an 
increased percentage (about 50%) of atretic antral follicles. However, these mice do not manifest 
an immediate decrease in fertility as a result of the increased number of atretic antral follicles, 
suggesting the possibility of a threshold in the percentage of atretic antral follicles that can cause 
infertility. Although, in our study we have shown that approximately 50% of antral follicle loss 
is not critical for reproduction, it does not rule out the possibility of premature reproductive 
senescence. 
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 This study has evaluated the dose-response curves of MXC over several time points using 
varying doses of the chemical with the hope of broadening our knowledge of the effects of MXC 
in the ovary. Although we used a single end-point to evaluate the dose-response data in these 
studies, it opens up a new avenue for us to explore the mechanism by which low versus high 
doses of MXC can cause differential effects in the ovary. An interesting future study would be to 
evaluate the levels of gene expression of apoptotic factors or cell-cycle regulators at these doses 
and treatment regimens to further investigate the non-monotonic effects of MXC. 
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5.6 Figures and Legends 
 
 
Figure 5.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluation of atresia in ovaries of CD-1 mice treated with vehicle, sesame oil (SES) or MXC 
(64, 128 and 160 mg/kg/day) for 5 days. Ovaries of treated mice were collected for histological 
evaluation of atresia in antral follicles and categorized as healthy or atretic by visual evaluation 
of apoptotic bodies. The percentage of atretic antral follicles were quantified and plotted as 
shown above. Each bar represents means ± SEM. (n = 3-4 mice/treatment group) 
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Figure 5.2 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluation of atresia in ovaries of CD-1 mice treated with SES or MXC (8, 16, 32, 64, 128 and 
160 mg/kg/day) for 10 days. Ovaries of treated mice were collected for histological evaluation of 
atresia in antral follicles and categorized as healthy or atretic by visual evaluation of apoptotic 
bodies. The percentage of atretic antral follicles were quantified and plotted as shown above. 
Each bar represents means ± SEM. Bars with different letters are significantly different from 
each other (n = 3-7 mice/treatment group; p≤0.05) 
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Figure 5.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluation of atresia in ovaries of CD-1 mice treated with SES or MXC (64 and 96 mg/kg/day) 
for 20 days. Ovaries of treated mice were collected for histological evaluation of atresia in antral 
follicles and categorized as healthy or atretic by visual evaluation of apoptotic bodies. The 
percentage of atretic antral follicles were quantified and plotted as shown above. Each bar 
represents means ± SEM. Asterisk (*) indicates significant difference from SES controls. (n = 10 
mice/treatment group; p≤0.05) 
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Figure 5.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluation of atresia in ovaries of CD-1 mice treated with SES or MXC (48, 64 and 96 
mg/kg/day) for 30 days. Ovaries of treated mice were collected for histological evaluation of 
atresia in antral follicles and categorized as healthy or atretic by visual evaluation of apoptotic 
bodies. The percentage of atretic antral follicles were quantified and plotted as shown above. 
Each bar represents means ± SEM. Asterisks (*) indicate significant differences from SES 
controls. (n = 10-20 mice/treatment group; p≤0.05) 
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Table 5.1 
 
 
Treatment Ovary Weight (g) (Paired; Mean ± S.E.) 
Litter Size (Live 
Pups; Mean ± S.E.) 
Individual Pup Weight (g) (Mean 
± S.E) 
SES 0.0429 ± 0.0141 11.222 ± 2.949 1.174 ± 0.199 
48 mg/kg/day 0.0295 ± 0.0064 10.200 ± 2.530 1.130 ± 0.213 
96 mg/kg/day 0.0312 ± 0.0036 9.556 ± 2.297 1.012 ± 0.217 
 
 
Adult female CD-1 mice were treated with SES or MXC (48 and 96 mg/kg/day) for 30 days and 
bred with untreated male mice. The pregnant dams were euthanized on GD 17 – 19 and the pups 
were collected. The ovarian weights of the treated dams, the litter size and individual pup 
weights were recorded as shown above. 
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CHAPTER VI 
	  
Conclusion	  
 
 
6.1 Conclusion 
 
 The purpose of this dissertation work was to determine whether endocrine disruption in 
the normal estrogenic pathway leads to altered sensitivity of the ovaries to environmental 
chemicals. In this dissertation, disruption of the estrogenic pathway was achieved by 
overexpressing ESR1 in the ESR1 OE mouse ovaries. Since MXC is considered a model 
endocrine disruptor and estrogenic chemical (Cummings, 1997), I hypothesized that ESR1 OE 
ovaries would have altered responses to MXC compared to normal mouse ovaries. It is important 
to study the mechanism of action of estrogenic chemicals including MXC because humans and 
wild-life species are exposed to thousands of chemicals that have not been examined for their 
ovarian toxicity.  A screening method for potential ovarian toxicants would provide important 
information about what chemicals are likely to pose a risk to mammals, including humans. 
Besides this, there is limited knowledge about how ovaries respond normally to estrogenic 
chemicals versus how they respond when normal estrogenic pathways are disrupted. Normal 
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estrogenic pathways may be disrupted after exposure to chemicals, by genetic polymorphisms or 
in cancerous tissues (Jefferson et al., 2002; Patisaul et al., 1999; Tanaka et al., 2003). 
 In Chapter 3, I have shown that ESR1 OE antral follicles are more sensitive to slow-
growth induced by MXC and its metabolites compared to controls. Moreover, MXC and its 
metabolites cause differential gene expression of nuclear receptors and metabolizing enzymes of 
MXC in ESR1 OE antral follicles compared to controls. Furthermore, in the livers of ESR1 OE 
mice, gene expression levels of Cyp3a4, which converts MOH and HPTE to soluble compounds 
for excretion (Stresser and Kupfer, 1997), are lower compared to controls. This suggests that the 
increased sensitivity of ESR1 OE mouse antral follicles to growth inhbition induced by MXC 
may be due to low clearance of these chemicals.  
 In Chapter 4, I have demonstrated that ESR1 OE antral follicles are more susceptible to 
atresia induced by MXC and its metabolites in vitro compared to controls. On analyzing 
activity/expression of pro-apoptotic factors, the activity levels of capsase3/7 and the gene 
expression levels of Bax and Bid was also found to be higher in ESR1 OE antral follicles treated 
with MXC in vitro compared to controls. I also carried out in vivo dosing experiments and found 
that ESR1 OE antral follicles were more susceptible to the atresia caused by the highest dose of 
MXC in vivo compared to controls. These findings were supported by protein expression data of 
pro-apoptotic factor pro-caspase-3 showing significantly lower amounts of pro-caspase-3 at the 
highest dose in ESR1 OE antral follicles, indicating cleavage of pro-caspase-3, compared to 
controls. 
 Collectively, I have explored two major pathways that may cause the increased 
susceptibility of ESR1 OE antral follicles to MXC compared to controls. In the first pathway, 
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increased sensitivity may occur because of low levels of Cyp3a4 in the livers of ESR1 OE mice 
compared to controls. Cyp3a4 is involved in converting the metabolites of MXC, MOH and 
HPTE to more soluble compounds for excretion. Hence, lower Cyp3a4 levels could lead to low 
clearance of the metabolites, causing them to linger in ESR1 OE mice longer than in controls. In 
the second pathway, MXC and its metabolites cause differential gene/protein expression levels 
of nuclear receptors and pro-apoptotic factors in ESR1 OE ovaries compared to controls. The 
differences in the expression levels of these factors caused by MXC and its metabolites may 
contribute either individually or synergistically to cause increased sensitivity of ESR1 OE 
ovaries to MXC compared to controls.  
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6.2 Figure & Legend 
Figure 6.1 
 
 
 
 
 
 
 
 
 
 
Block diagram illustrating the two pathways 1 & 2 by which ESR1 OE mice may be more 
susceptible to toxicity induced by MXC and its metabolites MOH and HPTE. Pathway 1 – the 
clearance of the metabolites of MXC is decreased due to lower expression levels of Cyp3a4 in 
the livers of ESR1 OE mice compared to controls. Pathway 2 – MXC causes differential 
expression/activity of nuclear receptors and pro-apoptotic factors in ESR1 OE mice compared to 
controls.  
1 
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